Abstract
Expressed sequence tags (ESTs) provide an imprint of cellular RNA diversity irrespectively of sequence homology with template genomes. NCBI databases include many unknown RNAs from various normal and cancer cells. These are usually ignored assuming sequencing artefacts or contamination due to their lack of sequence homology with template DNA. Here, we report genomic origins of 347 ESTs previously assumed artefacts/unknown, from the FAPESP/LICR Human Cancer Genome Project. EST template detection uses systematic nucleotide exchange analyses called swinger transformations. Systematic nucleotide exchanges replace systematically particular nucleotides with different nucleotides. Among 347 unknown ESTs, 51 ESTs match mitogenome transcription, 17 and 2 ESTs are from nuclear chromosome non-coding regions, and uncharacterized nuclear genes. Identified ESTs mapped on 205 protein-coding genes, 10 genes had swinger RNAs in several biosamples. Whole cell transcriptome searches for 17 ESTs mapping on non-coding regions confirmed their transcription. The 10 swinger-transcribed genes identified more than once associate with cancer induction and progression, suggesting swinger transformation occurs mainly in highly transcribed genes. Swinger transformation is a unique method to identify noncanonical RNAs obtained from NGS, which identifies putative ncRNA transcribed regions. Results suggest that swinger transcription occurs in highly active genes in normal and genetically unstable cancer cells.
Introduction
Systematic nucleotide exchanges, also called swinger transformations, systematically exchange specific nucleotides with other specific nucleotides during DNA replication and/or RNA transcription. DNA or RNA molecules corresponding to systematic nucleotide changes are called swinger DNAs or swinger RNAs. Only 23 systematic nucleotide exchanges (Figure 1) are possible with four nucleotide bases (A, T, C and G), i.e. nine symmetric (X ↔ Y, e.g. A ↔ G) (; ) and 14 asymmetric (X → Y → Z → X, e.g. A → G → T → A) (; ). For example, in symmetric exchange A ↔ G, all As are replaced by Gs and all Gs by As. The 14 asymmetric exchanges are directional, e.g. A → G → T → A: all As are replaced by Gs, Gs by Ts and Ts by As. It is unclear whether these systematic exchanges occur during DNA/RNA polymerizations or result from posttranscriptional editions. Their relatively long lengths (> 100 nucleotides) favors the former. Previous correlation analyses (; ; ) show that the lengths and abundances of swinger RNAs are approximately proportional to rates calculated on the basis of corresponding single nucleotide misinsertions by the human mitochondrial gamma DNA polymerase (from ). This suggests that swinger RNAs result from polymerizations where the polymerase is stabilized in the usually transient, unstable state that causes regular single nucleotide misinsertions.
Figure 1
Systematic nucleotide exchange analyses identify genomic origins of unknown DNA/RNA sequences. Several types of RNAs with no sequence homology to template genomes exist. This includes RNA-DNA differences (; ; ; ; ; ; ; ; ), post-transcriptional editing (; ; ; ; ; ), post-transcriptional hyper editing () and polymerase template switching (; ). Transcript fusion explains some noncanonical RNAs (; ; ). Some rare DNAs and RNAs seerm to result from spontaneous, template-free polymerization (; ). Due to the systematic nature of swinger transformations, identified, previously unknown sequence reads overcome the widely argued possibility of by-chance alignment with randomly amplified sequencing artefacts since randomness does not produce systematic exchanges.
Mitogenomic human swinger RNA reads produced by Illumina confirmed corresponding EST data (). The swinger transcriptome of the amoeban-hosted Mimivirus was also confirmed by two different sequencing techniques (SOLID and 454, ). Detected peptides matching translation of the swinger-transformed mitogenome tend to map on detected swinger RNAs (; ; ; ). These findings were further confirmed in purified mitochondrial transcriptomes (), rejecting the possibility of cytoplasmic contamination. Chimeric mitochondrial swinger RNAs also exist, partly following swinger polymerization and partly regular polymerization, with abrupt switches between these parts (; ). This observation is paralleled by chimeric peptides, corresponding to translation of adjacent regular and swinger RNA (). Swinger RNA coverage associates with secondary structure formation (). Swinger DNA also occurs (; ). Molecular functions and associations of swinger polymerizations with healthy or unhealthy cells remain unknown. Recently, swinger RNAs with A ↔ T + C ↔ G transformation were identified in HIV mediated Non-Hodgkin's Lymphoma (). The identified RNAs with A ↔ T + C ↔ G transformation are similar to the transcriptional product by polymerase template switching, known in retroviruses () and the human genome ().
The Encyclopedia of DNA Elements (ENCODE) project concluded that a human genome includes approximately 20,000 protein-coding genes and predicts that 80% of non-coding regions regulate gene expression (). However, the transcriptomes generated by current RNA sequencing technologies do not cover the complete human genome, because analyses of sequencing reads assume only canonical transcription. Analyses assuming systematic nucleotide exchanges could identify non-canonical RNAs and their genomic origin.
Expressed sequence tags (ESTs) are short DNA sequences (100–600 bp) generated from the sequencing of cDNA libraries. The ESTs represent RNAs derived from a particular cell irrespective of sequence similarity or dissimilarity to its template genome, unlike transcriptomes, in which sequencing reads with sequence similarity are considered as true reads while ignoring non-homologous reads. This underlines a major limitation in identifying and studying non-canonical RNAs and their association with various genetic diseases like cancers. Therefore, here we apply swinger transformations to identify unknown expressed sequence tags (ESTs) occurring in the FAPESP/LICR Human Cancer Genome Project (). We expect to identify unknown ESTs reported in cancer cells, identify and report their genomic origins and confirm that swinger-transformed RNAs occur beyond mitochondria.
Methods
Identification of Unknown Ests
The FAPESP/LICR Human Cancer Genome Project corresponds to 891,011 published () and 55,248 unpublished ESTs in the NCBI database. These ESTs were blasted with the “Human genomic + transcript” database using the “highly similar sequence” algorithm (megablast) (; ). A total of 149,500 ESTs with no sequence similarity with the human genome were further blasted across all sequences in the NCBI database to exclude ESTs corresponding to potential contaminations.
Swinger Transformation of Unknown Ests
The unknown 149,500 ESTs were then swinger-transformed according to the 23 bijective transformations (Figure 1) (). These 149,500 unknown ESTs were blasted again with the “Human genomic + transcript” database using megablast, in order to detect their genomic template.
Results and Discussion
In total, 347 ESTs (0.23%) were identified using swinger transformation analyses (Tables 1–3). This rate is 4× lower than that estimated for human mitochondria (about 100/10000 ESTs, 1% (data from ; ; ). Swinger-transformed sequences of these identified 347 ESTs are in Supplementary Table 1. The remaining 99.77% of unidentified ESTs could be sequencing artefacts. These could also be ESTs with non-systematic post-transcriptional hyper editing () or resulting from systematic nucleotide deletion transcription (). Among 347 ESTs, 223 ESTs were symmetrically transformed swinger RNAs (219 ESTs were A ↔ T transformed, two ESTs were A ↔ C transformed, and one of each was C ↔ T and G ↔ T transformed). The average length of alignment of A ↔ T, A ↔ C, C ↔ T and G ↔ T transformed ESTs was 325 bp, 225 bp, 196 bp, 152 bp with an average percentage identity of 96.95, 90.52, 96.42, and 89.47% respectively. Similarly, A → T → C → G → A transformed asymmetric swinger transformations account for 124 ESTs with 96.95% average percentage identity and 308 bp average alignment length. The largest aligned swinger RNA was 685 bp with 41 bp as the smallest. Unlike symmetrical transformations, ESTs identified as A → T → C → G → A transformed have to be transcribed assuming A → G → C → T → A from the template DNA region (Figure 2). From here on, these identified ESTs are considered swinger RNAs. Abundances of swinger RNA classes are proportional to their mean length (r = 0.96, two tailed P = 0.00945). Assuming that different swinger classes result from different polymerase states, the positive correlation indicates that the same factor that promotes switching to a given mode of swinger transcription also favors the stability of this mode. The opposite, indicated by a negative association, would mean that frequent types of switches are unstable. We suggest that systematic nucleotide transformations happen during transcription (swinger transcription). This might result from polymerase enzyme fatigue. In carcinogenesis, during malignant transformation, cancer cells produce mutated RNAs and proteins because of genetic instability (; ). Therefore, swinger RNAs are probably mainly non- or dys-functional, and produce non- and dysfunctional proteins with probable carcinogenic effects.
Table 1
| EST Acc No. | Biosample | Cancer tissue | EST Length | Swinger transformation | Aligned sequence AI | Chromosome | Gene | Aligned Seq. length | %ID | e-value | 5' | 3' |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AI902333.1 | SAMN00156544 | Breast | 173 | A ↔ C | NM_001278462.1 | 12 | MDM2 proto-oncogene (MDM2) | 100 | 97.000 | 2.37e−39 | 65 | 163 |
| AI903883.1 | SAMN00156581 | Breast | 193 | G ↔ T | NM_080386.3 | 2 | tubulin alpha 3d (TUBA3D) | 147 | 93.197 | 4.39e−57 | 1,095 | 950 |
| AI939933.1 | SAMN00156800 | Colon | 283 | A ↔ T | NM_001185092.1 | 1 | nitrilase 1 (NIT1) | 168 | 94.643 | 6.67e−67 | 402 | 238 |
| AI939934.1* | SAMN00156800 | Colon | 273 | A ↔ T | NM_001037333.2 | 5 | cytoplasmic FMR1 interacting protein 2 (CYFIP2) | 200 | 96.500 | 1.80e−87 | 738 | 540 |
| AI939935.1* | SAMN00156800 | Colon | 156 | A ↔ T | NM_001037333.2 | 5 | cytoplasmic FMR1 interacting protein 2 (CYFIP2) | 142 | 95.775 | 1.45e−58 | 733 | 592 |
| AI939936.1* | SAMN00156800 | Colon | 303 | A ↔ T | NM_001037333.2 | 5 | cytoplasmic FMR1 interacting protein 2 (CYFIP2) | 202 | 98.515 | 1.78e−97 | 741 | 540 |
| AI939937.1 | SAMN00156800 | Colon | 253 | A ↔ T | NM_001008491.2 | 2 | septin 2 (SEPT2) | 234 | 98.291 | 6.26e−112 | 2,935 | 2,703 |
| AI939938.1* | SAMN00156800 | Colon | 266 | A ↔ T | NM_001037333.2 | 5 | cytoplasmic FMR1 interacting protein 2 (CYFIP2) | 202 | 94.059 | 8.44e−81 | 541 | 741 |
| AI939939.1 | SAMN00156800 | Colon | 377 | A ↔ T | NW_019805496.1 | 11 | NADH:ubiquinone oxidoreductase core subunit S3 (NDUFS3) | 246 | 98.374 | 1.34e−118 | 10,294 | 10,049 |
| AI939940.1 | SAMN00156800 | Colon | 361 | A ↔ T | NM_001008491.2 | 2 | septin 2 (SEPT2) | 299 | 94.314 | 2.85e−125 | 2,905 | 2,608 |
| AI939941.1 | SAMN00156801 | Colon | 303 | A ↔ T | NM_001267774.1 | 17 | intraflagellar transport 20 (IFT20) | 220 | 98.182 | 1.05e−104 | 609 | 390 |
| AI939942.1 | SAMN00156801 | Colon | 182 | A ↔ T | NC_000008.11 | 8 | vir like m6A methyltransferase associated (VIRMA) | 77 | 97.403 | 5.45e−28 | 94,525,717 | 94,525,793 |
| AI939943.1 | SAMN00156801 | Colon | 312 | A ↔ T | NM_001282538.1 | 1 | G protein subunit beta 1 (GNB1) | 301 | 96.013 | 1.01e−134 | 1,212 | 1,512 |
| AI939947.1* | SAMN00156461 | Colon | 210 | A ↔ T | NM_001009570.2 | 2 | chaperonin containing TCP1 subunit 7 (CCT7) | 182 | 95.604 | 5.08e−78 | 1,127 | 946 |
| AI939949.1* | SAMN00156461 | Colon | 622 | A ↔ T | NM_001009570.2 | 2 | chaperonin containing TCP1 subunit 7 (CCT7) | 572 | 94.231 | 0.0 | 576 | 1,143 |
| AI939950.1* | SAMN00156461 | Colon | 512 | A ↔ T | NM_001009570.2 | 2 | chaperonin containing TCP1 subunit 7 (CCT7) | 484 | 98.347 | 0.0 | 1,183 | 702 |
| AI939951.1* | SAMN00156802 | Colon | 317 | A ↔ T | NR_037849.1 | 2 | WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA | 310 | 94.839 | 4.70e−133 | 1,103 | 796 |
| AI939953.1 | SAMN00156802 | Colon | 609 | A ↔ T | NM_001134671.2 | 8 | derlin 1 (DERL1) | 608 | 97.862 | 0.0 | 2,407 | 1,802 |
| AI939959.1* | SAMN00156802 | Colon | 218 | A ↔ T | NR_037849.1 | 2 | WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA | 219 | 97.717 | 6.34e−102 | 1,043 | 826 |
| AI939961.1* | SAMN00156802 | Colon | 231 | A ↔ T | NM_033017.3 | 7 | tripartite motif containing 4 (TRIM4) | 204 | 95.588 | 2.33e−86 | 2,432 | 2,633 |
| AI939962.1* | SAMN00156802 | Colon | 212 | A ↔ T | NM_001300821.2 | 12 | eukaryotic translation initiation factor 4B (EIF4B) | 160 | 96.250 | 6.67e−67 | 2,434 | 2,276 |
| AI939963.1* | SAMN00156802 | Colon | 340 | A ↔ T | NM_033017.3 | 7 | tripartite motif containing 4 (TRIM4) | 291 | 95.189 | 2.85e−125 | 2,629 | 2,344 |
| AI939965.1 | SAMN00156802 | Colon | 214 | A ↔ T | NR_038854.1 | 12 | negative regulator of antiviral response (non-protein coding) (NRAV), long non-coding RNA | 220 | 94.545 | 1.39e−88 | 632 | 848 |
| AI939966.1* | SAMN00156802 | Colon | 366 | A ↔ T | NR_037849.1 | 2 | WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA | 317 | 94.637 | 2.81e−135 | 1,717 | 2,032 |
| AI939968.1 | SAMN00156802 | Colon | 270 | A ↔ T | NC_000003.12 | 3 | CUB domain containing protein 1 (CDCP1) | 270 | 98.889 | 1.31e−133 | 45,123,674 | 45,123,943 |
| AI939969.1* | SAMN00156802 | Colon | 143 | A ↔ T | NM_001300821.2 | 12 | eukaryotic translation initiation factor 4B (EIF4B) | 123 | 98.374 | 6.63e−54 | 2,313 | 2,434 |
| AI939970.1* | SAMN00156802 | Colon | 255 | A ↔ T | NM_033017.3 | 7 | tripartite motif containing 4 (TRIM4) | 231 | 94.805 | 1.04e−96 | 2,406 | 2,633 |
| AI939972.1 | SAMN00156802 | Colon | 168 | A ↔ T | NC_000017.11 | 17 | target of myb1 like 2 membrane trafficking protein (TOM1L2) | 166 | 96.386 | 1.39e−70 | 17,849,628 | 17,849,465 |
| AI939973.1 | SAMN00156802 | Colon | 337 | A ↔ T | NR_037616.1 | 6 | thioredoxin domain containing 5 (TXNDC5) and BLOC1S5-TXNDC5 readthrough (NMD candidate) (BLOC1S5-TXNDC5), long non-coding RNA | 340 | 97.059 | 4.42e−160 | 1,880 | 1,542 |
| AI939976.1* | SAMN00156802 | Colon | 200 | A ↔ T | NR_037849.1 | 2 | WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA | 200 | 100.000 | 1.34e−100 | 1,785 | 1,984 |
| AI939980.1 | SAMN00156802 | Colon | 155 | A ↔ T | NM_144570.2 | 16 | Jupiter microtubule associated homolog 2 (JPT2) | 156 | 94.872 | 3.04e−62 | 2,949 | 2,794 |
| AI939981.1* | SAMN00156802 | Colon | 229 | A ↔ T | NR_037849.1 | 2 | WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA | 235 | 96.170 | 2.22e−103 | 1,996 | 1,762 |
| AI939988.1* | SAMN00156802 | Colon | 290 | A ↔ T | NR_037849.1 | 2 | WW domain binding protein 1 (WBP1) INO80B-WBP1 read through (NMD candidate) (INO80B-WBP1), long non-coding RNA | 280 | 96.786 | 7.71e−128 | 2,021 | 1,744 |
| AI940584.1* | SAMN00156483 | Head_neck | 583 | A ↔ T | NM_001166285.1 | 2 | chaperonin containing TCP1 subunit 7 (CCT7) | 568 | 93.838 | 0.0 | 1,890 | 1,326 |
| AW062762.1 | SAMN00156993 | Colon | 433 | A ↔ T | NM_001354666.1 | 3 | peroxisome proliferator activated receptor gamma (PPARG), transcript | 409 | 98.778 | 0.0 | 1,137 | 1,545 |
| AW062764.1 | SAMN00156993 | Colon | 610 | A ↔ T | NC_000002.12 | 2 | protein kinase C epsilon (PRKCE) | 491 | 99.389 | 0.0 | 45,959,855 | 45,959,366 |
| AW062765.1 | SAMN00156993 | Colon | 360 | A ↔ T | NC_000009.12 | 9 | sorting nexin family member 30 (SNX30) | 341 | 99.120 | 2.01e−173 | 112,811,006 | 112,811,345 |
| AW062769.1 | SAMN00156993 | Colon | 595 | A ↔ T | NM_001198773.2 | 1 | phosphatidylinositol 4-kinase beta (PI4KB) | 466 | 98.712 | 0.0 | 3,151 | 3,615 |
| AW062770.1 | SAMN00156993 | Colon | 589 | A ↔ T | NC_000016.10 | 16 | Rho GTPase activating protein 17 (ARHGAP17) | 586 | 99.147 | 0.0 | 24,921,862 | 24,922,445 |
| AW062771.1 | SAMN00156993 | Colon | 643 | A ↔ T | NM_006386.4 | 22 | DEAD-box helicase 17 (DDX17) | 605 | 96.694 | 0.0 | 1,878 | 2,480 |
| AW062772.1 | SAMN00156993 | Colon | 540 | A ↔ T | NM_000381.3 | X | midline 1 (MID1) | 519 | 99.037 | 0.0 | 5,758 | 5,240 |
| AW062773.1 | SAMN00156993 | Colon | 378 | A ↔ T | NM_002795.3 | 17 | proteasome subunit beta 3 (PSMB3) | 368 | 98.913 | 0.0 | 384 | 751 |
| AW062775.1 | SAMN00156993 | Colon | 650 | A ↔ T | NM_000358.2 | 5 | transforming growth factor beta induced (TGFBI) | 325 | 97.846 | 2.05e−158 | 1,166 | 1,489 |
| AW062776.1 | SAMN00156993 | Colon | 722 | A ↔ T | XM_017008304.2 | 4 | PREDICTED: Homo sapiens RNA binding motif protein 47 (RBM47) | 357 | 97.479 | 9.36e−172 | 1,924 | 2,280 |
| AW062777.1 | SAMN00156993 | Colon | 449 | A ↔ T | NM_001345950.1 | 10 | tripartite motif containing 8 (TRIM8) | 110 | 92.727 | 4.07e−36 | 1,009 | 901 |
| AW062778.1 | SAMN00156993 | Colon | 491 | A ↔ T | NC_000010.11 | 10 | C-terminal binding protein 2 (CTBP2) | 474 | 98.734 | 0.0 | 125,121,894 | 125,121,421 |
| AW062779.1 | SAMN00156993 | Colon | 252 | A ↔ T | NM_001136153.1 | 6 | activating transcription factor 6 beta (ATF6B) | 234 | 98.718 | 6.09e−114 | 1,207 | 1,440 |
| AW062782.1 | SAMN00156993 | Colon | 558 | A ↔ T | NC_000008.11 | 8 | ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1) | 356 | 95.787 | 3.41e−161 | 130,131,998 | 130,132,351 |
| AW062784.1 | SAMN00156993 | Colon | 542 | A ↔ T | NM_015397.3 | 9 | DDB1 and CUL4 associated factor 12 (DCAF12) | 326 | 97.546 | 4.45e−155 | 2,795 | 3,116 |
| AW062787.1 | SAMN00156993 | Colon | 647 | A ↔ T | NC_000012.12 | 12 | signal transducer and activator of transcription 2 | 608 | 91.776 | 0.0 | 56,349,156 | 56,348,551 |
| AW062788.1 | SAMN00156993 | Colon | 458 | A ↔ T | NC_000021.9 | 21 | VPS26 endosomal protein sorting factor C (VPS26C) | 293 | 97.611 | 4.54e−140 | 37,236,577 | 37,236,868 |
| AW062789.1 | SAMN00156993 | Colon | 685 | A ↔ T | NC_000017.11 | 17 | Myosin XVIIIA (MYO18A) | 406 | 98.276 | 0.0 | 29,141,358 | 29,141,763 |
| AW062792.1 | SAMN00156993 | Colon | 688 | A ↔ T | NM_001082480.2 | 8 | zinc finger protein 623 (ZNF623) | 671 | 97.914 | 0.0 | 3,041 | 3,707 |
| AW062793.1 | SAMN00156993 | Colon | 283 | A ↔ T | NC_000007.14 | 7 | PREDICTED: Homo sapiens speedy/RINGO cell cycle regulator family member E2B (SPDYE2B) | 206 | 84.466 | 1.86e−49 | 102,357,109 | 102,357,313 |
| AW062794.1 | SAMN00156993 | Colon | 115 | A ↔ T | NM_001282507.1 | 16 | PKD1P4-NPIPA8 readthrough (PKD1P4-NPIPA8), non-coding RNA+ nuclear pore complex interacting protein family member A7 (NPIPA7) | 98 | 96.939 | 2.43e−38 | 778 | 875 |
| AW062796.1 | SAMN00156993 | Colon | 196 | A ↔ T | NM_001256410.1 | 10 | RAB18, member RAS oncogene family (RAB18) | 183 | 98.361 | 1.37e−85 | 876 | 1,058 |
| AW062799.1 | SAMN00156993 | Colon | 316 | A ↔ T | NM_022130.3 | 5 | golgi phosphoprotein 3 (GOLPH3), transcript variant X1, mRNA | 276 | 98.551 | 1.27e−135 | 1,152 | 1,427 |
| AW062801.1 | SAMN00156993 | Colon | 263 | A ↔ T | NM_020700.1 | 12 | protein phosphatase, Mg2+/Mn2+ dependent 1H (PPM1H) | 245 | 99.592 | 6.00e−124 | 4,901 | 4,657 |
| AW062802.1 | SAMN00156993 | Colon | 360 | A ↔ T | NM_000610.3 | 11 | CD44 molecule (Indian blood group) (CD44), | 346 | 97.399 | 4.38e−165 | 2,799 | 2,454 |
| AW062803.1 | SAMN00156993 | Colon | 642 | A ↔ T | NM_005814.2 | 1 | glycoprotein A33 (GPA33), transcript variant X1, mRNA | 351 | 92.877 | 3.51e−141 | 825 | 1,171 |
| AW062804.1 | SAMN00156993 | Colon | 640 | A ↔ T | NM_000701.7 | 1 | ATPase Na+/K+ transporting subunit alpha 1 (ATP1A1 | 636 | 96.855 | 0.0 | 3,394 | 2,760 |
| AW062805.1 | SAMN00156993 | Colon | 622 | A ↔ T | NC_000009.12 | 9 | golgi membrane protein 1 (GOLM1) | 400 | 94.500 | 1.55e−174 | 86,074,944 | 86,075,342 |
| AW062807.1* | SAMN00156993 | Colon | 616 | A ↔ T | NM_001079524.1 | 4 | phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase (PAICS) | 582 | 88.144 | 0.0 | 1,737 | 2,276 |
| AW062808.1 | SAMN00156993 | Colon | 325 | A ↔ T | NM_015658.3 | 2 | NOC2 like nucleolar associated transcriptional repressor (NOC2L) | 290 | 98.621 | 7.55e−143 | 953 | 1,242 |
| AW062809.1 | SAMN00156993 | Colon | 609 | A ↔ T | NM_001278699.2 | 3 | RNA polymerase II subunit H (POLR2H) | 544 | 97.978 | 0.0 | 1,229 | 1,771 |
| AW062815.1* | SAMN00156993 | Colon | 621 | A ↔ T | NW_017852933.1 | 16 | nuclear pore complex-interacting protein family member A7-like (LOC102724993) | 606 | 98.515 | 0.0 | 1,699,909 | 1,699,305 |
| AW062818.1 | SAMN00156993 | Colon | 363 | A ↔ T | NC_000003.12 | 3 | coiled-coil-helix-coiled-coil-helix domain containing 6 (CHCHD6) | 349 | 98.281 | 7.23e−173 | 126,914,442 | 126,914,789 |
| AW062819.1 | SAMN00156993 | Colon | 524 | A ↔ T | NM_015658.3 | 1 | NOC2 like nucleolar associated transcriptional repressor (NOC2L) | 252 | 99.603 | 7.71e−128 | 991 | 1,242 |
| AW062820.1* | SAMN00156993 | Colon | 508 | A ↔ T | NM_001293298.1 | 15 | cell migration inducing hyaluronidase 1 (CEMIP) | 388 | 97.423 | 0.0 | 6,478 | 6,092 |
| AW062821.1* | SAMN00156993 | Colon | 336 | A ↔ T | NM_002295.5 | 3 | ribosomal protein SA (RPSA) | 329 | 95.441 | 9.69e−147 | 182 | 510 |
| AW062822.1 | SAMN00156993 | Colon | 350 | A ↔ T | NM_007278.1 | 17 | GABA type A receptor-associated protein (GABARAP) | 155 | 96.774 | 1.09e−66 | 650 | 497 |
| AW062823.1 | SAMN00156993 | Colon | 619 | A ↔ T | NM_001300832.2 | 11 | FERM domain containing 8 (FRMD8) | 499 | 98.998 | 0.0 | 2,751 | 2,253 |
| AW062824.1 | SAMN00156993 | Colon | 294 | A ↔ T | NM_001731.2 | 12 | BTG anti-proliferation factor 1 (BTG1), mRNA | 289 | 97.924 | 1.63e−139 | 1,410 | 1,122 |
| AW062825.1 | SAMN00156993 | Colon | 358 | A ↔ T | NM_002086.4 | 17 | growth factor receptor bound protein 2 (GRB2), transcr | 246 | 98.780 | 1.30e−120 | 2,793 | 3,038 |
| AW062826.1 | SAMN00156993 | Colon | 311 | A ↔ T | NC_000007.14 | 7 | PREDICTED: Homo sapiens speedy/RINGO cell cycle regulator family member E2B (SPDYE2B) | 206 | 84.466 | 1.86e−49 | 102,357,109 | 102,357,313 |
| AW062827.1 | SAMN00156993 | Colon | 500 | A ↔ T | NM_014455.3 | 1 | ring finger protein 115 (RNF115) | 380 | 99.474 | 0.0 | 1,064 | 685 |
| AW062828.1 | SAMN00156993 | Colon | 490 | A ↔ T | NM_001271969.1 | 6 | heat shock protein 90 alpha family class B member 1 (HSP90AB1), | 364 | 98.077 | 1.54e−179 | 2,091 | 1,730 |
| AW062829.1 | SAMN00156993 | Colon | 588 | A ↔ T | NM_001024216.2 | 1 | filamin binding LIM protein 1 (FBLIM1) | 525 | 99.048 | 0.0 | 2,354 | 2,877 |
| AW062830.1 | SAMN00156993 | Colon | 191 | A ↔ T | NM_003302.2 | 7 | thyroid hormone receptor interactor 6 (TRIP6) | 173 | 96.532 | 4.98e−75 | 1,639 | 1,467 |
| AW062831.1 | SAMN00156993 | Colon | 157 | A ↔ T | NM_003749.2 | 13 | insulin receptor substrate 2 (IRS2), mRNA | 144 | 94.444 | 5.12e−55 | 5,643 | 5,503 |
| AW175732.1* | SAMN00156993 | Colon | 392 | A ↔ T | NC_000015.10 | 15 | cell migration inducing hyaluronidase 1 (CEMIP) | 237 | 96.203 | 1.72e−104 | 80,878,828 | 80,879,064 |
| AW175733.1 | SAMN00156993 | Colon | 748 | A ↔ T | NM_032833.4 | 1 | protein phosphatase 1 regulatory subunit 15B (PPP1R15B) | 574 | 95.645 | 0.0 | 71 | 643 |
| AW175736.1 | SAMN00156993 | Colon | 391 | A ↔ T | NM_005080.3 | 22 | X-box binding protein 1 (XBP1) | 284 | 97.183 | 2.13e−133 | 497 | 779 |
| AW175738.1* | SAMN00156993 | Colon | 195 | A ↔ T | NC_000003.12 | 3 | chromosome 3 open reading frame 14 (C3orf14) | 137 | 95.620 | 6.63e−54 | 62,332,406 | 62,332,270 |
| AW175740.1* | SAMN00156993 | Colon | 382 | A ↔ T | NC_000008.11 | 8 | pericentriolar material 1 (PCM1) | 288 | 97.917 | 2.11e−138 | 17,968,415 | 17,968,700 |
| AW175741.1 | SAMN00156993 | Colon | 277 | A ↔ T | NC_000002.12 | 2 | phosphodiesterase 11A (PDE11A) | 203 | 95.567 | 3.80e−86 | 177,849,206 | 177,849,004 |
| AW175742.1 | SAMN00156993 | Colon | 701 | A ↔ T | NC_000001.11 | 1 | nuclear receptor subfamily 5 (NR5A2) | 190 | 98.421 | 1.75e−89 | 200,040,067 | 200,040,255 |
| AW175747.1* | SAMN00156993 | Colon | 182 | A ↔ T | NC_000012.12 | 12 | ribosomal protein SA pseudogene 52 (RPSAP52) | 122 | 92.623 | 5.23e−40 | 65,765,193 | 65,765,313 |
| AW175749.1 | SAMN00156993 | Colon | 379 | A ↔ T | NC_000003.12 | 2 | tigger transposable element also zinc finger protein 621 (ZNF621) derived 1 (TIGD1) | 244 | 98.361 | 7.82e−118 | 3,165,299 | 3,165,056 |
| AW175751.1 | SAMN00156993 | Colon | 403 | A ↔ T | NT_187585.1 | 11 | potassium voltage-gated channel subfamily Q member 1 (KCNQ1) | 336 | 94.048 | 4.54e−140 | 49,605 | 49,278 |
| AW175753.1 | SAMN00156993 | Colon | 800 | A ↔ T | NC_000005.10 | 5 | MCC regulator of WNT signaling pathway (MCC) | 140 | 84.286 | 6.87e−29 | 113,144,132 | 113,144,267 |
| AW176932.1* | SAMN00156993 | Colon | 655 | A ↔ T | NM_001079524.1 | 4 | phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase (PAICS) | 624 | 97.917 | 0.0 | 2,426 | 1,803 |
| AW176933.1* | SAMN00156993 | Colon | 286 | A ↔ T | NC_000012.12 | 12 | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 | 283 | 97.173 | 3.56e−131 | 110,285,901 | 110,285,620 |
| AW176934.1* | SAMN00156993 | Colon | 294 | A ↔ T | NC_000012.12 | 12 | ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 | 285 | 99.649 | 3.49e−146 | 110,285,904 | 110,285,620 |
| AW176938.1 | SAMN00156993 | Colon | 183 | A ↔ T | NM_014280.2 | 1 | DnaJ heat shock protein family (Hsp40) member C8 (DNAJC8), | 179 | 96.648 | 6.40e−79 | 661 | 483 |
| AW176940.1 | SAMN00156993 | Colon | 334 | A ↔ T | NC_000014.9 | 14 | serine palmitoyltransferase long chain base subunit 2 (SPTLC2) | 306 | 98.693 | 2.68e−152 | 77,544,607 | 77,544,912 |
| AW176941.1 | SAMN00156993 | Colon | 664 | A ↔ T | NC_000002.12 | 2 | MIR4435-2 host gene (MIR4435-2HG) | 580 | 98.276 | 0.0 | 111,301,721 | 111,302,299 |
| AW176942.1 | SAMN00156993 | Colon | 337 | A ↔ T | NM_001265603.1 | 15 | mortality factor 4 like 1 (MORF4L1) | 279 | 98.208 | 4.57e−135 | 565 | 843 |
| AW176943.1 | SAMN00156993 | Colon | 627 | A ↔ T | NC_000016.10 | 16 | membrane bound transcription factor peptidase, site 1(MBTPS1) | 500 | 98.200 | 0.0 | 84,061,142 | 84,061,638 |
| AW176945.1 | SAMN00156993 | Colon | 361 | A ↔ T | NM_030629.2 | 16 | c-Maf inducing protein (CMIP) | 326 | 98.466 | 9.49e−162 | 2,775 | 2,450 |
| AW176946.1 | SAMN00156993 | Colon | 664 | A ↔ T | NM_001873.3 | 4 | carboxypeptidase E (CPE) | 307 | 98.046 | 5.79e−149 | 1,193 | 890 |
| AW176947.1 | SAMN00156993 | Colon | 680 | A ↔ T | NC_000004.12 | 4 | huntingtin (HTT) | 660 | 98.485 | 0.0 | 3,200,416 | 3,201,074 |
| AW176948.1 | SAMN00156993 | Colon | 360 | A ↔ T | NM_001256799.2 | 12 | glyceraldehyde-3-phosphate dehydrogenase (GAPDH) | 311 | 99.357 | 2.05e−158 | 831 | 1,140 |
| AW176949.1 | SAMN00156993 | Colon | 304 | A ↔ T | NM_005731.3 | 2 | actin related protein 2/3 complex subunit 2 (ARPC2) | 272 | 94.118 | 7.87e−113 | 867 | 597 |
| AW176952.1 | SAMN00156993 | Colon | 629 | A ↔ T | NC_000002.12 | 2 | integrin subunit alpha 6 (ITGA6) | 630 | 99.841 | 0.0 | 172,430,001 | 172,429,372 |
| AW176953.1 | SAMN00156993 | Colon | 375 | A ↔ T | NM_001204510.1 | 17 | SENP3-EIF4A1 readthrough (NMD candidate) (SENP3-EIF4A1), long non-coding RNA+eukaryotic translation initiation factor 4A1 (EIF4A1) | 338 | 99.408 | 5.59e−174 | 824 | 487 |
| AW176954.1 | SAMN00156993 | Colon | 282 | A ↔ T | NM_006761.4 | 17 | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon (YWHAE),non-coding RNA | 264 | 98.485 | 2.14e−128 | 961 | 699 |
| AW176955.1 | SAMN00156993 | Colon | 470 | A ↔ T | NC_000007.14 | 10 | general transcription factor IIi | 264 | 100.000 | 3.54e−136 | 74,722,574 | 74,722,311 |
| AW176958.1 | SAMN00156993 | Colon | 255 | A ↔ T | NM_001291484.2 | 19 | carcinoembryonic antigen related cell adhesion molecule 5 (CEACAM5) | 227 | 99.119 | 1.02e−111 | 1,130 | 1,356 |
| AW176959.1* | SAMN00156993 | Colon | 682 | A ↔ T | NM_001402.5 | 6 | eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) | 647 | 92.427 | 0.0 | 923 | 1,566 |
| AW176960.1* | SAMN00156993 | Colon | 622 | A ↔ T | NM_001402.5 | 6 | eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) | 610 | 99.672 | 0.0 | 891 | 1,499 |
| AW176962.1 | SAMN00156993 | Colon | 309 | A ↔ T | NM_005514.7 | 6 | major histocompatibility complex, class I, B (HLA-B) | 276 | 97.464 | 1.28e−130 | 1,338 | 1,063 |
| AW176963.1* | SAMN00156993 | Colon | 451 | A ↔ T | NC_000001.11 | 1 | erythrocyte membrane protein band 4 (EPB41) | 381 | 98.163 | 0.0 | 29,114,294 | 29,113,915 |
| AW176964.1* | SAMN00156993 | Colon | 392 | A ↔ T | NC_000001.11 | 1 | erythrocyte membrane protein band 4 (EPB41) | 381 | 98.688 | 0.0 | 29,114,294 | 29,113,915 |
| AW176965.1 | SAMN00156993 | 1Colon | 628 | A ↔ T | NM_001137604.2 | 2 | RNA polymerase I subunit B (POLR1B) | 421 | 99.050 | 0.0 | 3,159 | 3,579 |
| AW176968.1 | SAMN00156993 | Colon | 633 | A ↔ T | NM_001172663.1 | 16 | RAB40C, member RAS oncogene family (RAB40C) | 160 | 98.750 | 1.79e−74 | 1,801 | 1,643 |
| AW176969.1 | SAMN00156993 | Colon | 348 | A ↔ T | NM_002588.3 | 5 | protocadherin gamma subfamily B, 3 (PCDHGB3) | 350 | 97.714 | 1.57e−169 | 4,400 | 4,051 |
| AW176971.1* | SAMN00156993 | Colon | 650 | A ↔ T | NM_001402.5 | 6 | eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) | 307 | 98.697 | 7.44e−153 | 1,305 | 1,000 |
| AW176972.1 | SAMN00156993 | Colon | 374 | A ↔ T | NM_001167671.2 | 3 | LIM domain containing preferred translocation partner in lipoma (LPP) | 369 | 98.103 | 0.0 | 16,859 | 17,225 |
| AW176973.1 | SAMN00156993 | Colon | 645 | A ↔ T | NC_000016.10 | 16 | zinc and ring finger 1 (ZNRF1) | 587 | 98.978 | 0.0 | 75,058,197 | 75,058,783 |
| AW176974.1 | SAMN00156993 | Colon | 652 | A ↔ T | NM_001276418.1 | 9 | SEC16 homolog A, endoplasmic reticulum export factor (SEC16A) | 585 | 99.316 | 0.0 | 8,695 | 8,111 |
| AW176982.1* | SAMN00156993 | Colon | 560 | A ↔ T | NC_012920.1 | mito | cox1 | 513 | 99.220 | 0.0 | 6,537 | 6,025 |
| AW903505.1* | SAMN00159106 | Nervous_normal | 436 | A → T → C → G → A | NR_148543.1 | 2 | clathrin heavy chain linker domain containing 1 (CLHC1) | 437 | 98.169 | 0.0 | 569 | 1,001 |
| AW903508.1 | SAMN00159106 | Nervous_normal | 443 | A → T → C → G → A | NM_015018.3 | 6 | DOP1 leucine zipper like protein A (DOP1A) | 362 | 99.448 | 0.0 | 7,625 | 7,264 |
| AW903509.1* | SAMN00159106 | Nervous_normal | 449 | A → T → C → G → A | NM_001351724.1 | 4 | Rap guanine nucleotide exchange factor 2 (RAPGEF2) | 451 | 97.561 | 0.0 | 5,954 | 6,400 |
| AW903510.1 | SAMN00159106 | Nervous_normal | 472 | A → T → C → G → A | NM_004859.3 | 17 | clathrin heavy chain (CLTC) | 406 | 99.015 | 0.0 | 3,799 | 4,202 |
| AW903511.1 | SAMN00159106 | Nervous_normal | 464 | A → T → C → G → A | NC_000014.9 | 14 | endoplasmic reticulum oxidoreductase 1 alpha (ERO1A) | 444 | 97.973 | 0.0 | 52,686,677 | 52,687,114 |
| AW903512.1* | SAMN00159106 | Nervous_normal | 185 | A → T → C → G → A | NM_024996.5 | 3 | G elongation factor mitochondrial 1 (GFM1) | 186 | 90.323 | 9.61e−61 | 3,446 | 3,264 |
| AW903513.1* | SAMN00159106 | Nervous_normal | 254 | A → T → C → G → A | NM_024996.5 | 3 | G elongation factor mitochondrial 1 (GFM1) | 166 | 100.000 | 2.60e−81 | 3,237 | 3,072 |
| AW903514.1* | SAMN00159106 | Nervous_normal | 423 | A → T → C → G → A | NM_001351724.1 | 4 | Rap guanine nucleotide exchange factor 2 (RAPGEF2) | 424 | 99.057 | 0.0 | 5,962 | 6,384 |
| AW903515.1 | SAMN00159106 | Nervous_normal | 447 | A → T → C → G → A | NC_000008.11 | 8 | mitochondrial calcium uptake family member 3 | 447 | 100.000 | 0.0 | 17,028,849 | 17,028,403 |
| AW903516.1* | SAMN00159106 | Nervous_normal | 446 | A → T → C → G → A | NM_007353.2 | 7 | G protein subunit alpha 12 (GNA12) | 409 | 99.511 | 0.0 | 3,841 | 4,249 |
| AW903517.1* | SAMN00159106 | Nervous_normal | 382 | A → T → C → G → A | NM_004529.3 | 9 | MLLT3, super elongation complex subunit (MLLT3) | 379 | 99.736 | 0.0 | 4,755 | 4,377 |
| AW903518.1* | SAMN00159106 | Nervous_normal | 261 | A → T → C → G → A | NC_012920.1 | mito | cox1 | 133 | 99.248 | 9.61e−61 | 6,634 | 6,766 |
| AW903519.1* | SAMN00159106 | Nervous_normal | 457 | A → T → C → G → A | NC_000001.11 | 1 | membrane associated guanylate kinase (MAGI3) | 443 | 97.065 | 0.0 | 113,403,203 | 113,403,645 |
| AW903520.1 | SAMN00159106 | Nervous_normal | 461 | A → T → C → G → A | NR_029435.1 | 14 | PSMA3 antisense RNA 1 (PSMA3-AS1), long non-coding RNA | 447 | 100.000 | 0.0 | 2,426 | 1,980 |
| AW903521.1* | SAMN00159106 | Nervous_normal | 449 | A → T → C → G → A | NC_012920.1 | mito | cox1 | 451 | 98.670 | 0.0 | 6,534 | 6,982 |
| AW903523.1 | SAMN00159106 | Nervous_normal | 447 | A → T → C → G → A | NC_000004.12 | 4 | NEDD4 binding protein 2 (N4BP2) | 445 | 99.775 | 0.0 | 40,063,375 | 40,063,375 |
| AW903524.1* | SAMN00159106 | Nervous_normal | 455 | A → T → C → G → A | NM_001286691.1 | 9 | MLLT3, super elongation complex subunit (MLLT3) | 449 | 100.000 | 0.0 | 4,671 | 4,223 |
| AW903525.1 | SAMN00159106 | Nervous_normal | 431 | A → T → C → G → A | NC_000003.12 | 3 | C-X9-C motif containing 1 (269) | 269 | 99.628 | 2.40e−136 | 28,242,970 | 28,242,702 |
| AW903526.1* | SAMN00159106 | Nervous_normal | 466 | A → T → C → G → A | NR_029435.1 | 14 | PSMA3 antisense RNA 1 (PSMA3-AS1) and long non-coding RNA | 456 | 99.781 | 0.0 | 2,426 | 1,971 |
| AW903527.1* | SAMN00159106 | Nervous_normal | 446 | A → T → C → G → A | NM_004529.3 | 9 | MLLT3, super elongation complex subunit (MLLT3) | 446 | 99.776 | 0.0 | 4,213 | 4,658 |
| AW903528.1* | SAMN00159106 | Nervous_normal | 461 | A → T → C → G → A | NR_148543.1 | 2 | clathrin heavy chain linker domain containing 1 (CLHC1) | 457 | 99.344 | 0.0 | 1,034 | 578 |
| AW903529.1 | SAMN00159106 | Nervous_normal | 464 | A → T → C → G → A | NR_049782.1 | 2 | sorting nexin 17 (SNX17) | 455 | 98.901 | 0.0 | 1,025 | 573 |
| AW903530.1 | SAMN00159106 | Nervous_normal | 418 | A → T → C → G → A | NM_004800.2 | 13 | transmembrane 9 superfamily member 2 (TM9SF2) | 395 | 98.734 | 0.0 | 2,509 | 2,115 |
| AW903531.1 | SAMN00159106 | Nervous_normal | 408 | A → T → C → G → A | NC_000022.11 | 22 | phosphatidylinositol 4-kinase alpha (PI4KA) | 407 | 97.543 | 0.0 | 20,799,225 | 20,799,629 |
| AW903532.1 | SAMN00159106 | Nervous_normal | 279 | A → T → C → G → A | NC_000003.12 | 3 | zinc finger protein 148 (ZNF148) | 194 | 98.969 | 5.50e−93 | 125,335,569 | 125,335,762 |
| AW903533.1* | SAMN00159106 | Nervous_normal | 473 | A → T → C → G → A | NM_001293092.1 | 7 | G protein subunit alpha 12 (GNA12) | 409 | 99.267 | 0.0 | 3,790 | 4,198 |
| AW903534.1* | SAMN00159106 | Nervous_normal | 469 | A → T → C → G → A | NC_000007.14 | 7 | ataxin 7 like 1 (ATXN7L1) | 461 | 99.132 | 0.0 | 105,869,501 | 105,869,961 |
| AW903537.1 | SAMN00159106 | Nervous_normal | 448 | A → T → C → G → A | NC_000016.10 | 16 | RNA binding fox-1 homolog 1 (RBFOX1) | 431 | 99.304 | 0.0 | 6,537,483 | 6,537,913 |
| AW903538.1 | SAMN00159106 | Nervous_normal | 454 | A → T → C → G → A | NC_000023.11 | X | euroligin 4 X-linked (NLGN4X) | 454 | 99.559 | 0.0 | 6,115,554 | 6,115,102 |
| AW903539.1* | SAMN00159106 | Nervous_normal | 321 | A → T → C → G → A | NC_000011.10 | 11 | chromosome 11 open reading frame 80 (C11orf80) | 248 | 93.952 | 9.08e−101 | 66,766,914 | 66,767,161 |
| AW903540.1 | SAMN00159106 | Nervous_normal | 329 | A → T → C → G → A | NC_000007.14 | 7 | family with sequence similarity 221 member A (FAM221A) | 329 | 100.000 | 6.36e−172 | 23,695,685 | 23,696,013 |
| AW903541.1* | SAMN00159106 | Nervous_normal | 470 | A → T → C → G → A | NC_000005.10 | 5 | teneurin transmembrane protein 2 (TENM2) | 455 | 99.341 | 0.0 | 167,499,052 | 167,499,506 |
| AW903542.1* | SAMN00159106 | Nervous_normal | 464 | A → T → C → G → A | NM_024996.5 | 3 | G elongation factor mitochondrial 1 (GFM1) | 455 | 99.560 | 0.0 | 2,980 | 3,434 |
| AW903543.1 | SAMN00159106 | Nervous_normal | 470 | A → T → C → G → A | NC_000001.11 | 1 | vacuolar protein sorting 72 homolog (VPS72) | 468 | 99.359 | 0.0 | 151,182,693 | 151,183,160 |
| AW903544.1* | SAMN00159106 | Nervous_normal | 458 | A → T → C → G → A | NM_018947.5 | 7 | cytochrome c, somatic (CYCS), mRNA | 460 | 99.130 | 0.0 | 703 | 245 |
| AW903545.1* | SAMN00159106 | Nervous_normal | 458 | A → T → C → G → A | NC_000005.10 | 5 | teneurin transmembrane protein 2 (TENM2) | 459 | 99.782 | 0.0 | 167,499,058 | 167,499,516 |
| AW903546.1 | SAMN00159106 | Nervous_normal | 236 | A → T → C → G → A | NC_000011.10 | 11 | GRB2 associated binding protein 2 (GAB2) | 154 | 97.403 | 2.05e−67 | 78,340,987 | 78,341,140 |
| AW903547.1* | SAMN00159106 | Nervous_normal | 441 | A → T → C → G → A | NC_000001.11 | 1 | membrane associated guanylate kinase (MAGI3) | 427 | 97.190 | 0.0 | 113,403,203 | 113,403,629 |
| AW903550.1 | SAMN00159106 | Nervous_normal | 460 | A → T → C → G → A | NM_172350.2 | 1 | CD46 molecule (CD46) | 462 | 99.134 | 0.0 | 2,971 | 2,510 |
| AW903551.1* | SAMN00159106 | Nervous_normal | 215 | A → T → C → G → A | NC_012920.1 | mito | cox1 | 109 | 99.083 | 2.11e−47 | 7,416 | 7,308 |
| AW903553.1 | SAMN00159106 | Nervous_normal | 468 | A → T → C → G → A | NM_001351562.1 | 9 | TLE family member 4 (TLE4) | 469 | 97.655 | 0.0 | 4176 | 4643 |
| AW903554.1* | SAMN00159106 | Nervous_normal | 357 | A → T → C → G → A | NM_018947.5 | 7 | cytochrome c, somatic (CYCS), mRNA | 355 | 99.155 | 0.0 | 682 | 328 |
| AW903556.1* | SAMN00159106 | Nervous_normal | 444 | A → T → C → G → A | NM_004529.3 | 9 | MLLT3, super elongation complex subunit (MLLT3) | 446 | 99.327 | 0.0 | 4,746 | 4,301 |
| AW903557.1 | SAMN00159106 | Nervous_normal | 458 | A → T → C → G → A | NC_000012.12 | 12 | synaptotagmin 1 (SYT1) | 462 | 98.701 | 0.0 | 79,289,394 | 79,288,933 |
| AW903558.1 | SAMN00159106 | Nervous_normal | 476 | A → T → C → G → A | NC_000012.12 | 12 | kinesin family member 21A (KIF21A) | 477 | 99.161 | 0.0 | 39,406,699 | 39,407,174 |
| AW903559.1 | SAMN00159106 | Nervous_normal | 453 | A → T → C → G → A | NC_000017.11 | 17 | dynein axonemal heavy chain 17 (DNAH17) | 290 | 99.310 | 6.59e−147 | 78,428,317 | 78,428,606 |
| AW903560.1 | SAMN00159106 | Nervous_normal | 459 | A → T → C → G → A | NC_000006.12 | 6 | capping protein regulator and myosin 1 linker 1 (CARMIL1) | 403 | 96.030 | 0.0 | 25,338,780 | 25,338,379 |
| AW903561.1* | SAMN00159106 | Nervous_normal | 463 | A → T → C → G → A | NC_000014.9 | 14 | PSMA3 antisense RNA 1 (PSMA3-AS1) and long non-coding RNA | 449 | 98.886 | 0.0 | 58,265,829 | 58,265,381 |
| AW903563.1* | SAMN00159106 | Nervous_normal | 427 | A → T → C → G → A | NM_001352634.1 | 8 | pericentriolar material 1 (PCM1) | 423 | 99.291 | 0.0 | 5,954 | 6,376 |
| AW903564.1 | SAMN00159106 | Nervous_normal | 457 | A → T → C → G → A | NM_025054.4 | 8 | valosin containing protein interacting protein 1 (VCPIP1) | 374 | 99.198 | 0.0 | 7,603 | 7,976 |
| AW903565.1* | SAMN00159106 | Nervous_normal | 434 | A → T → C → G → A | NC_000007.14 | 7 | ataxin 7 like 1 (ATXN7L1) | 427 | 99.297 | 0.0 | 105,869,531 | 105,869,956 |
| AW903566.1 | SAMN00159106 | Nervous_normal | 283 | A → T → C → G → A | NM_015541.2 | 3 | leucine rich repeats and immunoglobulin like domains 1 (LRIG1) | 190 | 98.421 | 1.54e−88 | 3,447 | 3,258 |
| AW903567.1 | SAMN00159106 | Nervous_normal | 444 | A → T → C → G → A | NC_000022.11 | 22 | RNA binding fox-1 homolog 2 (RBFOX2) | 344 | 92.442 | 3.11e−135 | 35,867,779 | 35,868,118 |
| AW903568.1 | SAMN00159106 | Nervous_normal | 428 | A → T → C → G → A | NM_020755.3 | 6 | serine incorporator 1 (SERINC1) | 326 | 99.080 | 1.07e−164 | 2,332 | 2,008 |
| AW903570.1 | SAMN00159106 | Nervous_normal | 454 | A → T → C → G → A | NT_187614.1 | 17 | aminopeptidase puromycin sensitive pseudogene (NPEPPS1) | 200 | 97.000 | 1.54e−88 | 2,236,540 | 2,236,343 |
| AW903571.1 | SAMN00159106 | Nervous_normal | 480 | A → T → C → G → A | NM_001242866.2 | 21 | protein arginine methyltransferase 2 (PRMT2) | 297 | 99.663 | 1.82e−152 | 1,248 | 952 |
| AW903573.1* | SAMN00159106 | Nervous_normal | 336 | A → T → C → G → A | NC_012920.1 | mito | cox1 | 236 | 98.729 | 1.15e−114 | 7,112 | 7,347 |
| AW903576.1 | SAMN00159106 | Nervous_normal | 472 | A → T → C → G → A | NM_203401.1 | 4 | stathmin 1 (STMN1) | 468 | 98.932 | 0.0 | 361 | 827 |
| AW903577.1 | SAMN00159106 | Nervous_normal | 466 | A → T → C → G → A | NC_000007.14 | 7 | LUC7 like 2 (LUC7L2), pre-mRNA splicing factor | 461 | 98.915 | 0.0 | 139,362,483 | 139,362,023 |
| BE085177.1* | SAMN00159564 | Breast | 269 | A → T → C → G → A | NC_000010.11 | 10 | protein tyrosine phosphatase receptor type E (PTPRE) | 242 | 98.347 | 6.87e−117 | 127,960,155 | 127,959,914 |
| BE085178.1 | SAMN00159564 | Breast | 176 | A → T → C → G → A | NM_015888.4 | 1 | hook microtubule tethering protein 1 (HOOK1) | 171 | 92.982 | 2.67e−61 | 2,185 | 2,024 |
| BE085183.1 | SAMN00159564 | Breast | 293 | A → T → C → G → A | NC_000010.11 | 10 | SMC5-SMC6 complex localization factor 2 (SLF2) | 92 | 95.652 | 5.99e−33 | 100,947,017 | 100,947,107 |
| BE085186.1* | SAMN00159564 | Breast | 302 | A → T → C → G → A | NM_002840.4 | 1 | protein tyrosine phosphatase, receptor type F (PTPRF) | 268 | 96.642 | 2.45e−121 | 2,985 | 2,724 |
| BE085188.1 | SAMN00159564 | Breast | 280 | A → T → C → G → A | NM_007042.4 | 3 | ribonuclease P/MRP subunit p14 (RPP14) | 193 | 96.373 | 1.55e−83 | 328 | 139 |
| BE085197.1 | SAMN00159564 | Breast | 196 | A → T → C → G → A | NM_001281724.2 | 3 | biotinidase (BTD) | 106 | 99.057 | 2.73e−46 | 2,275 | 2,170 |
| BE085202.1 | SAMN00159564 | Breast | 170 | A → T → C → G → A | NM_021009.6 | 12 | ubiquitin C (UBC) | 102 | 89.216 | 1.01e−25 | 1,869 | 1,772 |
| BE145238.1 | SAMN00157869 | Head_neck | 333 | A ↔ T | NM_001042465.2 | 10 | prosaposin (PSAP) | 334 | 97.904 | 1.50e−163 | 1,739 | 2,072 |
| BE145239.1* | SAMN00157869 | Head_neck | 293 | A ↔ T | NM_001104629.1 | 4 | chromosome 4 open reading frame 19 (C4orf19) | 292 | 97.260 | 5.59e−138 | 1,828 | 2,119 |
| BE145240.1 | SAMN00157869 | Head_neck | 169 | A ↔ T | NM_001033925.1 | 10 | TIA1 cytotoxic granule associated RNA binding protein like 1 (TIAL1) | 169 | 96.450 | 4.73e−74 | 1,013 | 1,181 |
| BE145242.1 | SAMN00157869 | Head_neck | 452 | A ↔ T | NM_022470.3 | 3 | zinc finger matrin-type 3 (ZMAT3) | 404 | 98.267 | 0.0 | 6,273 | 6,675 |
| BE145243.1 | SAMN00157869 | Head_neck | 110 | A ↔ T | NM_001101662.1 | 1 | nardilysin convertase (NRDC) | 110 | 99.091 | 1.76e−48 | 1,445 | 1,336 |
| BE145245.1 | SAMN00157869 | Head_neck | 421 | A ↔ T | NC_000005.10 | 5 | small integral membrane protein 3 (SMIM3) | 416 | 97.837 | 0.0 | 150,784,346 | 150,784,758 |
| BE145246.1 | SAMN00157869 | Head_neck | 266 | A ↔ T | NM_001033047.2 | 4 | nephronectin (NPNT) | 267 | 92.884 | 9.75e−106 | 391 | 656 |
| BE145247.1 | SAMN00157869 | Head_neck | 359 | A ↔ T | NW_019805496.1 | 11 | mitochondrial carrier 2 (MTCH2) | 356 | 96.067 | 5.39e−163 | 55,682 | 56,035 |
| BE145248.1* | SAMN00157869 | Head_neck | 247 | A ↔ T | NC_000014.9 | 14 | valosin containing protein lysine methyltransferase (VCPKMT) | 240 | 92.083 | 9.96e−91 | 50,108,378 | 50,108,617 |
| BE145250.1* | SAMN00157869 | Head_neck | 289 | A ↔ T | NC_000014.9 | 14 | valosin containing protein lysine methyltransferase (VCPKMT) | 290 | 95.517 | 1.58e−128 | 50,108,285 | 50,108,574 |
| BE145251.1 | SAMN00157869 | Head_neck | 329 | A ↔ T | NC_000009.12 | 9 | spectrin alpha, non-erythrocytic 1 (SPTAN1) | 330 | 96.061 | 9.15e−151 | 128,610,482 | 128,610,155 |
| BF332836.1 | SAMN00160205 | Breast | 298 | A → T → C → G → A | NC_000001.11 | 1 | putative homeodomain transcription factor 1 (PHTF1) | 230 | 95.652 | 4.22e−99 | 113,710,355 | 113,710,126 |
| BF332837.1 | SAMN00160205 | Breast | 376 | A → T → C → G → A | NC_000002.12 | 2 | BCL2 like 11(BCL2 L11) | 241 | 98.340 | 3.20e−115 | 111,159,962 | 111,160,199 |
| BF332838.1 | SAMN00160205 | Breast | 359 | A → T → C → G → A | NC_000008.11 | 8 | integrator complex subunit 9 (INTS9) | 237 | 97.468 | 1.16e−109 | 28,784,748 | 28,784,981 |
| BF332840.1 | SAMN00160205 | Breast | 300 | A → T → C → G → A | NM_018364.4 | 1 | round spermatid basic protein 1 (RSBN1) | 209 | 94.737 | 1.20e−84 | 3,267 | 3,062 |
| BF332841.1 | SAMN00160205 | Breast | 372 | A → T → C → G → A | NM_002266.3 | 17 | karyopherin subunit alpha 2 (KPNA2) | 269 | 96.654 | 6.82e−122 | 2,022 | 1,757 |
| BF332842.1 | SAMN00160205 | Breast | 378 | A → T → C → G → A | NM_003761.4 | 2 | vesicle associated membrane protein 8 (VAMP8) | 253 | 99.209 | 8.76e−126 | 296 | 548 |
| BF332846.1 | SAMN00160205 | Breast | 280 | A → T → C → G → A | NM_017409.3 | 12 | homeobox C10 (HOXC10) | 190 | 95.789 | 4.35e−79 | 1,958 | 1,773 |
| BF332847.1 | SAMN00160205 | Breast | 405 | A → T → C → G → A | NC_000007.14 | 7 | 3-hydroxyisobutyrate dehydrogenase (HIBADH) | 275 | 97.818 | 2.42e−131 | 27,629,869 | 27,629,596 |
| BF332849.1 | SAMN00160205 | Breast | 308 | A → T → C → G → A | NC_000014.9 | 14 | dishevelled associated activator of morphogenesis 1 (DAAM1) | 206 | 95.631 | 1.99e−87 | 59,268,775 | 59,268,570 |
| BF332850.1 | SAMN00160205 | Breast | 383 | A → T → C → G → A | NC_000012.12 | 12 | spermatogenesis associated serine rich 2 (SPATS2) | 296 | 96.284 | 4.02e−134 | 49,458,046 | 49,457,752 |
| BF332851.1 | SAMN00160205 | Breast | 335 | A → T → C → G → A | NC_000013.11 | 13 | SMAD family member 9 (SMAD9) | 249 | 98.394 | 8.83e−121 | 36,916,214 | 36,916,462 |
| BF332854.1 | SAMN00160205 | Breast | 293 | A → T → C → G → A | NC_000003.12 | 3 | coiled-coil domain containing 66 (CCDC66) | 221 | 98.190 | 4.19e−104 | 56,561,670 | 56,561,451 |
| BF332855.1 | SAMN00160205 | Breast | 309 | A → T → C → G → A | NC_000014.9 | 14 | RAD51 paralog B (RAD51B) | 222 | 96.396 | 1.97e−97 | 68,178,422 | 68,178,203 |
| BF353453.1 | SAMN00161174 | Head_neck | 395 | A ↔ T | NM_002274.3 | 17 | keratin 13 (KRT13) | 53 | 100.000 | 8.30e−19 | 1,679 | 1,627 |
| BF354529.1* | SAMN00160318 | Head neck | 397 | A → T → C → G → A | NM_015596.2 | 19 | kallikrein related peptidase 13 (KLK13) | 317 | 98.107 | 1.09e−154 | 1,348 | 1,664 |
| BF354541.1 | SAMN00160318 | Head neck | 363 | A → T → C → G → A | NM_030634.2 | 1 | zinc finger protein 436 (ZNF436) | 295 | 98.644 | 8.52e−146 | 3,915 | 4,209 |
| BF354544.1 | SAMN00160318 | Head neck | 449 | A → T → C → G → A | NC_000006.12 | 6 | protein phosphatase 1 regulatory subunit 10 (PPP1R10) | 384 | 98.698 | 0.0 | 30,600,715 | 30,601,097 |
| BF354553.1 | SAMN00160318 | Head neck | 387 | A → T → C → G→ A | NW_016107297.1 | 5 | GUSB Pseudogene (GUSBP1) | 332 | 98.193 | 1.79e−162 | 163,285 | 162,954 |
| BF354559.1 | SAMN00160318 | Head neck | 193 | A → T → C → G → A | XM_011524110.3 | 17 | small G protein signaling modulator 2 (SGSM2) | 99 | 93.939 | 5.99e−33 | 2,457 | 2,360 |
| BF354564.1* | SAMN00160318 | Head neck | 402 | A → T → C → G → A | NM_015596.2 | 19 | kallikrein related peptidase 13 (KLK13) | 306 | 98.366 | 1.09e−149 | 1,359 | 1,664 |
| BF354572.1 | SAMN00160318 | Head neck | 389 | A → T → C → G → A | XM_011514699.2 | 6 | glucose-fructose oxidoreductase domain containing 1 (GFOD1) | 346 | 98.844 | 3.80e−174 | 3,008 | 3,353 |
| BF370229.1 | SAMN00160862 | Prostate_normal | 282 | A → T → C → G → A | NM_000138.4 | 15 | fibrillin 1 (FBN1) | 127 | 95.276 | 5.87e−48 | 8,263 | 8,388 |
| BF370230.1 | SAMN00160862 | Prostate_normal | 282 | A → T → C → G → A | NM_006887.4 | 15 | ZFP36 ring finger protein like 2 (ZFP36L2) | 346 | 97.399 | 3.85e−164 | 2,544 | 2,201 |
| BF370232.1 | SAMN00160862 | Prostate_normal | 410 | A → T → C → G → A | NC_012920.1 | mito | atp6 | 359 | 98.329 | 6.31e−177 | 8,663 | 9,020 |
| BF370233.1 | SAMN00160862 | Prostate_normal | 437 | A → T → C → G → A | NC_000023.11 | x | ubiquitin specific peptidase 9 X-linked (USP9X) | 373 | 98.928 | 0.0 | 41,186,360 | 41,185,989 |
| BF370234.1 | SAMN00160862 | Prostate_normal | 413 | A → T → C → G → A | NC_000012.12 | 12 | lysine demethylase 5A (KDM5A) | 349 | 97.994 | 2.96e−170 | 326,420 | 326,075 |
| BF370235.1 | SAMN00160862 | Prostate_normal | 294 | A → T → C → G → A | NM_001288733.1 | 17 | testis expressed 2 (TEX2) | 127 | 98.425 | 9.68e−56 | 4,533 | 4,659 |
| BF370236.1 | SAMN00160862 | Prostate_normal | 294 | A → T → C → G → A | NC_000009.12 | 9 | basonuclin 2 (BNC2) | 194 | 98.969 | 5.50e−93 | 16,514,557 | 16,514,750 |
| BF370237.1 | SAMN00160862 | Prostate_normal | 423 | A → T → C → G → A | NM_001146227.1 | 8 | ribosomal protein S20 (RPS20) | 304 | 99.013 | 6.54e−152 | 493 | 191 |
| BF370238.1 | SAMN00160862 | Prostate_normal | 332 | A → T → C → G → A | NC_000004.12 | 4 | sec1 family domain containing 2 (SCFD2) | 243 | 98.354 | 2.47e−116 | 52,874,276 | 52,874,518 |
| BF370239.1 | SAMN00160862 | Prostate_normal | 355 | A → T → C → G → A | NM_018046.4 | 5 | angiogenic factor with G-patch and FHA domains 1 (AGGF1) | 293 | 98.294 | 1.43e−143 | 4,058 | 4,350 |
| BF370241.1 | SAMN00160862 | Prostate_normal | 305 | A → T → C → G → A | NC_000017.11 | 17 | tubulin folding cofactor D (TBCD) | 173 | 98.844 | 2.60e−81 | 82,761,458 | 82,761,630 |
| BF370242.1 | SAMN00160862 | Prostate_normal | 250 | A → T → C → G → A | NC_000001.11 | 1 | GNG12, DIRAS3 and WLS antisense RNA 1 (GNG12-AS1) and Wnt ligand secretion mediator (WLS) | 127 | 98.425 | 9.68e−56 | 68,182,918 | 68,182,792 |
| BF370243.1 | SAMN00160862 | Prostate_normal | 413 | A → T → C → G → A | NC_000005.10 | 5 | ubiquitin conjugating enzyme E2 D2 (UBE2D2) | 272 | 97.059 | 8.76e−126 | 139,610,960 | 139,610,690 |
| BF798643.1 | SAMN00162090 | Colon_ins | 420 | A ↔ T | NR_045104.1 | 15 | integrator complex subunit 14 (INTS14) | 290 | 92.759 | 5.75e−114 | 163 | 448 |
| BF798647.1 | SAMN00162090 | Colon_ins | 415 | A ↔ T | NC_012920.1 | mito | 12s | 271 | 94.096 | 3.46e−111 | 915 | 649 |
| BF798651.1 | SAMN00162090 | Colon_ins | 363 | A ↔ T | NM_032593.2 | 9 | histidine triad nucleotide binding protein 2 (HINT2) | 57 | 94.737 | 5.12e−15 | 429 | 484 |
| BF798653.1 | SAMN00162090 | Colon_ins | 425 | A ↔ T | NC_012920.1 | mito | 12s | 270 | 94.815 | 5.75e−114 | 649 | 915 |
| BF798654.1 | SAMN00162090 | Colon_ins | 375 | A ↔ T | NM_001291920.1 | 9 | retinoid X receptor alpha (RXRA) | 136 | 95.588 | 8.10e−53 | 2,040 | 2,170 |
| BF798660.1 | SAMN00162090 | Colon_ins | 464 | A ↔ T | NC_012920.1 | mito | 12s | 269 | 97.398 | 1.22e−125 | 649 | 915 |
| BF798665.1 | SAMN00162090 | Colon_ins | 485 | A ↔ T | NM_004069.4 | 19 | adaptor related protein complex 2 sigma 1 subunit (AP2S1) | 373 | 98.123 | 0.0 | 564 | 193 |
| BF798667.1 | SAMN00162090 | Colon_ins | 521 | A ↔ T | NM_005561.3 | 13 | lysosomal associated membrane protein 1 (LAMP1) | 481 | 95.842 | 0.0 | 392 | 872 |
List of swinger transformed ESTs identified using BLAST. The list includes ESTs identified using swinger transformations and mapped on genes identified only in one biosamples.
Genes corresponding to more than one EST sequence are indicated by *.
Table 2
| EST Acc No. | Biosample | Cancer tissue | Length of EST | Swinger transformation | Acc. No. of aligned sequence | Chrom-osome | Gene | Aligned Seq. length | %ID | evalue | 5' | 3' |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BE085181.1 | SAMN00159564 | Breast | 109 | A → T → C → G → A | NC_012920.1 | mito | 16s | 41 | 95.122 | 6.21e−08 | 2,885 | 2,924 |
| BE085203.1 | SAMN00159564 | Breast | 282 | A → T → C → G → A | NC_012920.1 | mito | 16s | 189 | 98.413 | 1.54e−88 | 1,950 | 1,764 |
| BE085205.1 | SAMN00159564 | Breast | 134 | A → T → C → G → A | NC_012920.1 | mito | 16s | 89 | 97.753 | 1.29e−34 | 2,882 | 2,794 |
| BE085207.1 | SAMN00159564 | Breast | 245 | A → T → C → G → A | NC_012920.1 | mito | 16s | 185 | 97.838 | 1.20e−84 | 2,838 | 3,021 |
| BF332839.1 | SAMN00160205 | Breast | 249 | A → T → C → G → A | NC_012920.1 | mito | 16s | 156 | 97.436 | 5.70e−68 | 2,258 | 2,105 |
| BF798658.1 | SAMN00162090 | Colon_ins | 624 | A ↔ T | NC_012920.1 | mito | 16s+trnaL+ND1 | 464 | 98.276 | 0.0 | 3,075 | 3,537 |
| BF798678.1 | SAMN00162090 | Colon_ins | 589 | A ↔ T | NC_012920.1 | mito | 16s+trnaL+ND1 | 464 | 97.414 | 0.0 | 3,075 | 3,537 |
| AI939948.1 | SAMN00156461 | Colon | 529 | A ↔ T | NM_000476.2 | 9 | adenylate kinase 1 (AK1) | 504 | 97.024 | 0.0 | 198 | 700 |
| AI940588.1 | SAMN00156483 | Head_neck | 650 | A ↔ T | NM_001318121.1 | 9 | adenylate kinase 1 (AK1) | 574 | 98.606 | 0.0 | 177 | 749 |
| BF332844.1 | SAMN00160205 | Breast | 251 | A → T → C → G → A | NM_000100.3 | 21 | cystatin B (CSTB) | 170 | 96.471 | 7.32e−72 | 452 | 287 |
| AW176935.1 | SAMN00156993 | Colon | 386 | A ↔ T | NC_000021.9 | 21 | cystatin b (CSTB) | 349 | 99.140 | 2.58e−177 | 43,774,237 | 43,774,583 |
| AW176936.1 | SAMN00156993 | Colon | 368 | A ↔ T | NC_000021.9 | 21 | cystatin b (CSTB) | 348 | 99.425 | 5.55e−179 | 43,774,237 | 43,774,583 |
| AW903549.1 | SAMN00159106 | Nervous_normal | 444 | A → T → C → G → A | NM_001308390.1 | 18 | DLG associated protein 1 (DLGAP1) | 446 | 99.327 | 0.0 | 4,908 | 4,464 |
| AW176970.1 | SAMN00156993 | Colon | 701 | A ↔ T | NC_000020.11 | 20 | DLG associated protein 4 (DLGAP4) | 685 | 98.686 | 0.0 | 36,525,990 | 36,526,674 |
| BF332852.1 | SAMN00160205 | Breast | 406 | A → T → C → G → A | NM_153201.3 | 11 | heat shock protein family A (Hsp70) member 8 (HSPA8) | 302 | 97.351 | 1.84e−142 | 925 | 626 |
| BF798649.1 | SAMN00162090 | Colon_ins | 529 | A ↔ T | NM_006597.5 | 11 | heat shock protein family A (Hsp70) member 8 (HSPA8) | 486 | 95.062 | 0.0 | 386 | 865 |
| AW062795.1 | SAMN00156993 | Colon | 639 | A ↔ T | NM_005120.2 | X | mediator complex subunit 12 (MED12) | 502 | 99.801 | 0.0 | 4,475 | 3,974 |
| BF332843.1 | SAMN00160205 | Breast | 340 | A → T → C → G → A | NM_005121.2 | 17 | mediator complex subunit 13 (MED13) | 214 | 98.131 | 9.08e−101 | 943 | 731 |
| BF332848.1 | SAMN00160205 | Breast | 372 | A → T → C → G → A | NM_001271811.1 | 12 | mediator complex subunit 21 (MED21) | 245 | 97.959 | 2.47e−116 | 1,097 | 854 |
| AW176957.1 | SAMN00156993 | Colon | 517 | A ↔ T | NC_012920.1 | mito | nd1 | 495 | 99.192 | 0.0 | 3,663 | 4,157 |
| BF798657.1 | SAMN00162090 | Colon_ins | 363 | A ↔ T | NC_012920.1 | mito | nd1 | 210 | 93.333 | 1.30e−80 | 3,333 | 3,537 |
| AW903507.1 | SAMN00159106 | Nervous_normal | 215 | A → T → C → G → A | NC_012920.1 | mito | nd2 | 214 | 99.533 | 2.51e−106 | 4,739 | 4,952 |
| BF332853.1 | SAMN00160205 | Breast | 308 | A → T → C → G → A | NC_012920.1 | mito | nd2 | 216 | 99.074 | 9.02e−106 | 4,724 | 4,939 |
| BF354531.1 | SAMN00160318 | Head neck | 373 | A → T → C → G → A | NC_012920.1 | mito | nd2 | 242 | 98.760 | 1.48e−118 | 4,482 | 4,723 |
| BF354537.1 | SAMN00160318 | Head neck | 345 | A → T → C → G → A | NC_012920.1 | mito | nd2 | 232 | 100.000 | 5.31e−118 | 4,492 | 4,723 |
| BI032899.1 | SAMN00162655 | Nervous_normal | 424 | A ↔ C | NC_012920.1 | mito | nd2 | 351 | 84.046 | 2.80e−87 | 5,371 | 5,033 |
| AI939946.1 | SAMN00156461 | Colon | 488 | A ↔ T | NC_012920.1 | mito | nd2 | 393 | 97.710 | 0.0 | 5,062 | 4,670 |
| AI939952.1 | SAMN00156802 | Colon | 263 | A ↔ T | NC_012920.1 | mito | nd2 | 236 | 95.339 | 8.21e−101 | 4,958 | 4,723 |
| AI939954.1 | SAMN00156802 | Colon | 252 | A ↔ T | NC_012920.1 | mito | nd2 | 225 | 96.444 | 2.95e−100 | 4,945 | 4,723 |
| AI939955.1 | SAMN00156802 | Colon | 212 | A ↔ T | NC_012920.1 | mito | nd2 | 113 | 99.115 | 1.14e−49 | 4,905 | 4,794 |
| AI939956.1 | SAMN00156802 | Colon | 200 | A ↔ T | NC_012920.1 | mito | nd2 | 186 | 98.387 | 6.48e−87 | 4,930 | 4,746 |
| AI939957.1 | SAMN00156802 | Colon | 269 | A ↔ T | NC_012920.1 | mito | nd2 | 218 | 97.706 | 2.28e−101 | 4,751 | 4,967 |
| AI939958.1 | SAMN00156802 | Colon | 223 | A ↔ T | NC_012920.1 | mito | nd2 | 198 | 96.465 | 6.48e−87 | 4,919 | 4,723 |
| AI939960.1 | SAMN00156802 | Colon | 286 | A ↔ T | NC_012920.1 | mito | nd2 | 245 | 94.694 | 2.28e−101 | 4,962 | 4,723 |
| AI939964.1 | SAMN00156802 | Colon | 251 | A ↔ T | NC_012920.1 | mito | nd2 | 229 | 96.070 | 2.95e−100 | 4,949 | 4,723 |
| AI939967.1 | SAMN00156802 | Colon | 281 | A ↔ T | NC_012920.1 | mito | nd2 | 245 | 97.551 | 3.74e−114 | 4,723 | 4,967 |
| AI939971.1 | SAMN00156802 | Colon | 251 | A ↔ T | NC_012920.1 | mito | nd2 | 240 | 92.500 | 1.36e−90 | 4,962 | 4,723 |
| AI939974.1 | SAMN00156802 | Colon | 243 | A ↔ T | NC_012920.1 | mito | nd2 | 231 | 94.805 | 3.74e−96 | 4,952 | 4,723 |
| AI939975.1 | SAMN00156802 | Colon | 152 | A ↔ T | NC_012920.1 | mito | nd2 | 152 | 96.711 | 5.05e−65 | 4,898 | 4,748 |
| AI939977.1 | SAMN00156802 | Colon | 226 | A ↔ T | NC_012920.1 | mito | nd2 | 201 | 95.522 | 1.37e−85 | 4,922 | 4,723 |
| AI939978.1 | SAMN00156802 | Colon | 212 | A ↔ T | NC_012920.1 | mito | nd2 | 188 | 97.340 | 1.77e−84 | 4,914 | 4,729 |
| AI939979.1 | SAMN00156802 | Colon | 162 | A ↔ T | NC_012920.1 | mito | nd2 | 163 | 95.706 | 3.02e−67 | 4,949 | 4,789 |
| AI939982.1 | SAMN00156802 | Colon | 248 | A ↔ T | NC_012920.1 | mito | nd2 | 233 | 95.708 | 3.72e−101 | 4,955 | 4,723 |
| AI939984.1 | SAMN00156802 | Colon | 233 | A ↔ T | NC_012920.1 | mito | nd2 | 214 | 94.393 | 2.93e−87 | 4,933 | 4,723 |
| AI939985.1 | SAMN00156802 | Colon | 145 | A ↔ T | NC_012920.1 | mito | nd2 | 122 | 96.721 | 1.86e−49 | 4,847 | 4,967 |
| AI939986.1 | SAMN00156802 | Colon | 166 | A ↔ T | NC_012920.1 | mito | nd2 | 163 | 93.865 | 8.45e−63 | 4,891 | 4,729 |
| AI940581.1 | SAMN00156483 | Head_neck | 533 | A ↔ T | NC_012920.1 | mito | nd2 | 392 | 99.490 | 0.0 | 4,671 | 5,062 |
| AI940582.1 | SAMN00156483 | Head_neck | 509 | A ↔ T | NC_012920.1 | mito | nd2 | 393 | 99.237 | 0.0 | 4,670 | 5,062 |
| AI940585.1 | SAMN00156483 | Head_neck | 475 | A ↔ T | NC_012920.1 | mito | nd2 | 394 | 96.701 | 0.0 | 4,670 | 5,062 |
| AI940586.1 | SAMN00156483 | Head_neck | 296 | A ↔ T | NC_012920.1 | mito | nd2 | 294 | 98.299 | 5.83e−144 | 4,692 | 4,984 |
| AI940587.1 | SAMN00156483 | Head_neck | 474 | A ↔ T | NC_012920.1 | mito | nd2 | 393 | 99.237 | 0.0 | 5,062 | 4,670 |
| BF354521.1 | SAMN00160318 | Head neck | 383 | A → T → C → G → A | NC_012920.1 | mito | nd4 | 343 | 95.335 | 2.35e−151 | 11,016 | 11,354 |
| CK327105.1 | SAMN00157633 | Colon | 474 | A ↔ T | NC_012920.1 | mito | nd4 | 391 | 99.233 | 0.0 | 11,611 | 11,999 |
| BF370011.1 | SAMN00160853 | Prostate normal | 252 | C ↔ T | NC_012920.1 | mito | nd4 | 196 | 96.429 | 2.65e−85 | 11,610 | 11,801 |
| AW062763.1 | SAMN00156993 | Colon | 624 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 387 | 97.674 | 0.0 | 1,882 | 1,497 |
| AW062774.1 | SAMN00156993 | Colon | 673 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.753 | 0.0 | 1,889 | 1,485 |
| AW062781.1 | SAMN00156993 | Colon | 197 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 186 | 99.462 | 1.36e−90 | 1,707 | 1,523 |
| AW062786.1 | SAMN00156993 | Colon | 583 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.012 | 0.0 | 1,889 | 1,485 |
| AW062790.1 | SAMN00156993 | Colon | 685 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 95.309 | 0.0 | 1,888 | 1,485 |
| AW062791.1 | SAMN00156993 | Colon | 533 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.012 | 0.0 | 1,889 | 1,485 |
| AW062797.1 | SAMN00156993 | Colon | 331 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 321 | 99.065 | 2.64e−162 | 1,485 | 1,805 |
| AW062798.1 | SAMN00156993 | Colon | 312 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 303 | 97.690 | 1.25e−145 | 1,503 | 1,805 |
| AW062806.1 | SAMN00156993 | Colon | 472 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 409 | 99.511 | 0.0 | 1,893 | 1,485 |
| AW062810.1 | SAMN00156993 | Colon | 625 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 625 | 99.520 | 0.0 | 2,430 | 1,806 |
| AW062811.1 | SAMN00156993 | Colon | 426 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.753 | 0.0 | 1,485 | 1,889 |
| AW062812.1 | SAMN00156993 | Colon | 420 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 404 | 99.257 | 0.0 | 1,486 | 1,889 |
| AW062813.1 | SAMN00156993 | Colon | 688 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 100.000 | 0.0 | 1,889 | 1,485 |
| AW062814.1 | SAMN00156993 | Colon | 443 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.012 | 0.0 | 1,485 | 1,889 |
| AW062816.1 | SAMN00156993 | Colon | 536 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.753 | 0.0 | 1,485 | 1,889 |
| AW062817.1 | SAMN00156993 | Colon | 250 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 221 | 93.665 | 4.91e−85 | 1,574 | 1,781 |
| AW176937.1 | SAMN00156993 | Colon | 360 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 346 | 97.977 | 7.29e−168 | 1,485 | 1,825 |
| AW176944.1 | SAMN00156993 | Colon | 603 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.012 | 0.0 | 1,889 | 1,485 |
| AW176950.1 | SAMN00156993 | Colon | 419 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 86 | 100.000 | 3.15e−37 | 1,804 | 1,889 |
| AW176951.1 | SAMN00156993 | Colon | 192 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 142 | 100.000 | 2.33e−68 | 1,748 | 1,889 |
| AW176956.1 | SAMN00156993 | Colon | 348 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 319 | 99.060 | 3.41e−161 | 1,485 | 1,803 |
| AW176966.1 | SAMN00156993 | Colon | 497 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.506 | 0.0 | 1,889 | 1,485 |
| AW176967.1 | SAMN00156993 | Colon | 158 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 159 | 97.484 | 1.39e−70 | 1,917 | 2,074 |
| AW176975.1 | SAMN00156993 | Colon | 481 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 373 | 97.855 | 0.0 | 1,485 | 1,854 |
| AW176976.1 | SAMN00156993 | Colon | 605 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 354 | 88.701 | 2.17e−118 | 1,834 | 1,485 |
| AW176977.1 | SAMN00156993 | Colon | 639 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.259 | 0.0 | 1,889 | 1,485 |
| AW176978.1 | SAMN00156993 | Colon | 434 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 407 | 99.017 | 0.0 | 1,485 | 1,889 |
| AW176979.1 | SAMN00156993 | Colon | 599 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 406 | 99.507 | 0.0 | 1,485 | 1,889 |
| AW176980.1 | SAMN00156993 | Colon | 426 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.012 | 0.0 | 1,485 | 1,889 |
| AW176981.1 | SAMN00156993 | Colon | 599 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 405 | 99.012 | 0.0 | 1,889 | 1,485 |
| BF333938.1 | SAMN00157869 | Head_neck | 665 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 79 | 100.000 | 2.92e−33 | 1,563 | 1,485 |
| BF333939.1 | SAMN00157869 | Head_neck | 611 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 319 | 98.746 | 1.89e−159 | 1,803 | 1,485 |
| BF333940.1 | SAMN00157869 | Head_neck | 509 | A ↔ T | NM_002568.3 | 8 | poly(A) binding protein cytoplasmic 1 (PABPC1) | 311 | 91.318 | 4.33e−116 | 1,792 | 1,485 |
List of ESTs based on the genes identified in more than one biosample.
Table 3
| EST Acc No. | Biosample | Cancer tissue | Length of EST | Swinger transformation | Acc No of aligned sequence | Chromosome | Gene | Aligned Seq. length | %ID | evalue | 5' | 3' |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AI939983.1 | SAMN00156802 | Colon | 379 | A ↔ T | NC_000009.12 | 9 | Non-coding region | 360 | 97.778 | 4.32e−175 | 120,855,482 | 1,21E+08 |
| AI939987.1 | SAMN00156802 | Colon | 367 | A ↔ T | NC_000009.12 | 9 | Non-coding region | 345 | 97.971 | 7.29e-168 | 120,855,464 | 1,21E+08 |
| AW062766.1 | SAMN00156993 | Colon | 457 | A ↔ T | NC_000016.10 | 16 | Non-coding region | 313 | 99.681 | 9.49e−162 | 74,318,755 | 74319067 |
| AW175734.1 | SAMN00156993 | Colon | 328 | A ↔ T | NC_000004.12 | 4 | Non-coding region | 136 | 90.441 | 1.12e−41 | 131,268,224 | 1,31E+08 |
| AW175735.1 | SAMN00156993 | Colon | 620 | A ↔ T | NC_000004.12 | 4 | Non-coding region | 191 | 95.288 | 1.78e−79 | 131,268,167 | 1,31E+08 |
| AW175739.1 | SAMN00156993 | Colon | 222 | A ↔ T | NC_000008.11 | 8 | Non-coding region | 139 | 97.122 | 1.83e−59 | 102,600,346 | 1,03E+08 |
| AW175744.1 | SAMN00156993 | Colon | 506 | A ↔ T | NC_000008.11 | 8 | Non-coding region | 313 | 97.764 | 3.46e−151 | 88,009,959 | 88,009,648 |
| AW903506.1 | SAMN00159106 | Nervous_normal | 422 | A → T → C → G → A | NC_000006.12 | 6 | Non-coding region | 350 | 97.143 | 8.28e−166 | 132,009,130 | 1,32E+08 |
| AW903535.1 | SAMN00159106 | Nervous_normal | 440 | A → T → C → G → A | NC_000013.11 | 13 | Non-coding region | 442 | 99.321 | 0.0 | 95,650,104 | 95,650,545 |
| AW903555.1 | SAMN00159106 | Nervous_normal | 434 | A → T → C → G → A | NC_000010.11 | 10 | Non-coding region | 436 | 99.312 | 0.0 | 20,554,187 | 20,553,752 |
| AW903569.1 | SAMN00159106 | Nervous_normal | 430 | A → T → C → G → A | NC_000004.12 | 4 | Non-coding region | 357 | 98.599 | 1.36e−178 | 17,483,414 | 17,483,770 |
| AW903572.1 | SAMN00159106 | Nervous_normal | 248 | A → T → C → G → A | NC_000013.11 | 13 | Non-coding region | 56 | 100.000 | 3.66e−20 | 95,650,461 | 95,650,406 |
| BE085219.1 | SAMN00159564 | Breast | 314 | A → T → C → G → A | NC_000003.12 | 3 | Non-coding region | 311 | 97.749 | 3.94e−149 | 169,791,191 | 1,7E+08 |
| BF332859.1 | SAMN00160205 | Breast | 211 | A → T → C → G → A | NC_000020.11 | 20 | Non-coding region | 143 | 90.210 | 2.12e−42 | 59,862,273 | 59,862,140 |
| BF332861.1 | SAMN00160205 | Breast | 364 | A → T → C → G → A | NC_000010.11 | 10 | Non-coding region | 256 | 97.266 | 4.11e−119 | 8,810,014 | 8,810,267 |
| BF354533.1 | SAMN00160318 | Head neck | 388 | A → T → C → G → A | NC_000005.10 | 5 | Non-coding region | 331 | 99.698 | 2.29e−171 | 69,932,968 | 69,933,298 |
| BF370228.1 | SAMN00160862 | Prostate_normal | 264 | A → T → C → G → A | NC_000023.11 | x | Non-coding region | 195 | 95.897 | 2.01e−82 | 136,928,879 | 1,37E+08 |
| AW062783.1 | SAMN00156993 | Colon | 640 | A ↔ T | NC_000009.12 | 9 | Uncharacterized LOC101927086 | 557 | 75.404 | 5.09e−60 | 70,473,455 | 70,472,931 |
| BF798648.1 | SAMN00162090 | Colon_ins | 344 | A ↔ T | NC_000003.12 | 3 | Uncharacterized LOC102723512 | 148 | 96.622 | 2.87e−62 | 4,006,872 | 4,006,726 |
List of ESTs mapped on non-coding genomic regions and uncharacterized genes.
Figure 2
Swinger-Transformed Genes in Different Cancer Tissues
These 347 swinger-transformed RNAs matched 205 known and two uncharacterized genes (Tables 1–3). These identified swinger RNAs might be artefacts. However, among these 207 genes, swinger RNAs from 10 genes were detected in multiple cancer types and biosamples (Table 2). These genes are adenylate kinase 1 (AK1), cystatin B (CSTB), DLG associated protein (DLGAP), heat shock protein family A (Hsp70) member 8 (HSPA8), mediator complex subunits (MED), poly(A) binding protein cytoplasmic 1 (PABPC1), MT-16s rRNA, MT-ND1, MT-ND2 and MT-ND4.
Two A ↔ T-transformed swinger RNAs detected in the colon and head-neck cancer lines mapped on the adenylate kinase 1 (AK1) coding gene (Table 2). AK1 plays an important role in tumor suppression and it is often downregulated in cancer cells (; ; ; ). Three swinger RNAs detected in breast (A → G → C → T → A) and two colon cancer (A ↔ T) lines mapped on cystatin B (CSTB) (Table 2). CSTB plays an important role in expression and epigenetic regulation and is downregulated in lung, gastric and colorectal cancers (; ). CSTB promotes cell proliferation, migration and suppresses apoptosis in gastric cancer cells (). Downregulation of CSTB also promotes gastric cancer (). Similarly, swinger RNAs for HSPA8 and PABPC1 were identified. We identified two swinger RNAs from the HSPA8 protein-coding region. The carboxy-terminus of Hsc70 interacting protein (CHIP) plays an important role in cancer initiation and progression (; ; ) and has an anti-tumor effect in many cancer types including colon and gastric cancers (; ; ; ; ; ). Thirty-three swinger RNAs were transcribed from the PABPC1 gene from colon cancer and head-neck cancer biosamples, respectively (Table 2). PABPC proteins are RNA processing proteins associated with gene expression regulation () and are upregulated in prostate and colorectal cancers (). PABPC also has a tumor suppressor role in head and neck squamous cell carcinoma (). Swinger-transformed RNAs produced from these identified genes will produce non-homologous and putatively nonfunctional mRNAs translating dysfunctional nonhomologous proteins, which supports the association between downregulation of these genes and cancer cell types. These swinger RNAs could be early stage factors responsible for cancer induction or result from genetic instability in later stages of malignant cancers (; ). Results favor the former because the swinger transformed mRNA of tumor suppressor genes would result in disruption of gene function inhibiting programmed cell death. Analyses also identify two swinger RNAs mapped on DLG associated proteins (DLGAP1 and DLGAP4) coding genes in healthy nervous tissue samples and colon cancer cells. DLGAP is a protein overexpressed in the brain () and promotes invasiveness in cancer cell lines (). Similarly, three swinger RNAs were transcribed from mediator complex subunit genes (MED) in colon and breast cancer tissues (Table 2). Mutations in MED12 are associated with tumorigenesis (; ) and cause benign breast fibroepithelial lesions (). These two observations suggest that swinger transformation of MED should induce carcinogenesis, whereas, swinger RNAs are transcribed from overexpressing DLGAP genes due to enzyme fatigue in cancer cells.
Among the detected swinger RNAs, 51 swinger RNAs match mitochondrial genes (Tables 1 and 2). It is widely known and proven that mitochondrial genes are overexpressed in various cancer types to meet up the metabolic requirements of cancer cells and are strongly associated with cancer (; ; ; ). Among 51 swinger RNAs, 7, 1, 30 and 3 swinger RNAs are transcribed from mitochondrial 16s rRNA, ND1, ND2 and ND4, respectively. These were identified in several biosamples (Table 2). Sixty-six percent (33 ESTs) of the identified swinger RNAs were transcribed from the MT-ND region. A previous study showed bias for swinger transformation of MT-ND genes ().
Interestingly, detection of swinger transformed DLGAP1 mRNAs (overexpressed ~15× in neurons compared to other tissue cells; ), in normal nervous tissue samples suggests that the swinger transformation is not directly associated with cancer but perhaps associated with highly expressed genes. Carcinogenesis could be the outcome of swinger transformed dysfunctional mRNAs. Previously identified swinger RNAs from highly active cancer-associated genes () also support this finding. Indeed, even within mitochondrial genes, rRNAs are more expressed than other genes, and swinger rRNAs are the most frequently observed mitochondrial swinger RNAs in previous publications (; ; ; ), matching the pattern of positive association between regular and swinger transcriptions. Hence, the positive association between expression and swinger transformation occurs independently for human nuclear and mitochondrial genes. Hence, at least at this qualitative level of analysis, observations on these highly expressed nuclear and mitochondrial genes support that swinger transformations associate with highly active genomic regions that result in cancer induction and progression due to nonfunctional transcripts.
In order to test whether swinger transformations are biased towards some regions of genes, genes for which swinger RNAs were detected in more than one biosample (Table 2) are regionally compartmentalized in three equal regions i.e. 5' region, mid region and 3' regions, each region spanning 1/3 of the gene. Mitochondrial genes like 16S rRNA (five of seven ESTs), ND4 (two of three ESTs), and nuclear gene Cystatin B (three of three ESTs) mapped on the 3' extremity of their respective genes.
Among the 30 ESTs mapped on ND2 gene across multiple biosamples, 28 mapped on the central region (5' to 3'; 4,692 to 4,984 bp) of the mitochondrial genome (NC_012920.1), while two mapped on the 5' terminal of ND2 (4,482–4723 bp) gene. Interestingly, for MT-ND4, among the three ESTs identified across three different biosamples for three different swinger transformations, two ESTs mapped on the same 3' terminal ND4 region i.e. 11,610–11,801 bp on the mitochondrial genome (NC_012920.1). For Nuclear gene poly(A) binding protein cytoplasmic 1 (PABPC1), all the 33 identified ESTs preferentially mapped on the mid-region (5' 1,485 bp to 3' 1,803 bp on NM_002568.3) of PABPC1 gene.
Considering mitochondrial and nuclear genes separately, 38 among 43 (mitochondrial, 88.4%, one tailed sign test P = 0.0011) and 33 among 33 (nuclear, 100%, one tailed sign test P = 1.6 × 10−6) swinger RNAs map either on the mid or the 3' regions of the gene. These tests assume that the probability of mapping randomly on these regions is 2/3. One tailed sign tests are justified by the working hypothesis that polymerase enzyme fatigue (occurring more downstream from transcription initiation) causes swinger transcription. These observations indicate that the mid and 3' regions of highly expressed genes are more prone to produce swinger transformed RNAs than the 5' region, for each nuclear and mitochondrial genes. Similarly, swinger transformed ESTs (from only one biosample) mapping on identified genes, preferentially mapped on the same region (Table 1 shows the 5' and 3' positions of such ESTs).
Among 275 ESTs from nuclear protein coding genes, 196 ESTs mapped on exons of genes and 76 swinger transformed ESTs mapped on gene introns. Three ESTs mapped partly on gene exons and partly on introns, suggesting that swinger transformations occur before post transcriptional modification, and support our working hypothesis of swinger polymerization during replication/transcription.
The 347 ESTs correspond to 203 protein coding genes and 19 RNAs from non-coding regions. The median and mean size of a protein coding gene in human genome are ~26,288 bp and ~66,577 bp (). The mean and median length of identified 203 swinger transformed protein coding genes (including mitochondrial genes) are 124,427 bp and 55,291 bp which is almost twice the mean and median lengths of human protein coding genes. These genes for which swinger transcripts were detected also included the largest protein coding gene in the human genome i.e. RNA binding fox-1 homolog 1 (RBFOX1). These observations indicate that swinger transformation probably due to polymerase fatigue is not only associated to highly active genes but could also associate with large genes. This could also explain the biased mapping of swinger RNAs on the mid and 3' regions of genes, vs the first third of genes.
Swinger RNAs From Non-Coding and Uncharacterized Genomic Regions
Seventeen and two identified swinger RNAs were transcribed from 15 non-coding genomic regions and two uncharacterized genomic regions, respectively (Table 3). The 15 non-coding swinger RNAs were not from 5' or 3' UTR or intronic regions of protein-coding genes. To test if these 15 identified genomic regions on various human chromosomes are transcriptionally active, we did a transcriptome search in seventy-one samples (SRX768406–SRX768476, ) with the identified swinger RNAs transcribed from these non-coding genomic regions. Good and complete alignments of the reads on the searched sequences confirmed transcriptions of these 15 non-coding regions (Supplementary Table 2). This result suggests that these 15 regions are transcriptionally active, with potential roles in nerve cells and possible associations with carcinogenesis. However, these specific cancer tissue samples are unavailable, preventing further in-vitro and in-vivo tests and analyses.
The identified swinger RNAs were mapped on human nuclear chromosomes. No compartmentalizations on any chromosomal arm, region or band of a chromosome were detected in relation to swinger expressed regions. Swinger RNAs produced by transformations that are more conservative at the amino acid level are also more abundant than swinger RNAs produced by transformations that cause more amino acid changes (). This effect was also observed when comparing transformations involving the same number of nucleotides in the transformation (2, 3 or 4). For the distribution of swinger RNAs detected in the present study, too few classes of transformations were detected to enable such subdivisions. However, when considering all transformations, conservation increases with swinger RNA abundances (r = 0.4187, one tailed P = 0.0234). C ↔ G is the least conservative among the transformations involving only two nucleotides, and is one among two transformations for which no swinger RNA was detected in the currently examined data.
Conclusion
We report genomic origins of 347 previously unidentified ESTs generated by the FAPESP/LICR Human Cancer Genome Project (). These represent 0.23% of the 149,500 unidentified ESTs from that project. Note that other types of systematic transformations apparently produce non-canonical RNAs, such as systematic deletions, which produce so-called delRNAs (; ; ; ; ) and corresponding peptides (; ; ; ; ; ), including chimeric peptides (). This underlines a general approach to identify unknown sequences generated by various sequencing methods. This study identifies swinger RNAs transcribed from multiple cancer-associated genes (Tables 1 and 2), suggesting highly active genes produce swinger transcripts possibly due to enzyme fatigue and promoting cancer progression. The identified sequences might be sequencing artefacts. However, random artefacts generated by sequencing equipment could not produce systematic exchanges. Systematic sequencing errors should produce swinger RNAs for all sequenced ESTs, however, biosamples where swinger RNAs are detected include regular canonical RNAs. Analyses also identify transcriptionally active non-coding regions on human chromosomes discovering putative ncRNA transcribing regions with potentially significant roles in normal and cancer cells. We provide a unique method to study and identify unknown sequencing reads, reducing loss of important genetic information in raw sequence data. Systematic editing of RNA might contribute to solve the dark DNA conundrum.
Funding
This work was supported by the A*MIDEX project (no ANR-11-IDEX-0001-02) funded by the « Investissements d'Avenir » French Government program, managed by the French National Research Agency (ANR).
Statements
Data availability statement
All datasets generated for this study are included in the article/Supplementary Material.
Author contributions
GW conducted design, analysis, observation and writing. P-EF contributed to result assessments. HS designed the systematic nucleotide exchange framework. P-EF and HS contributed to writing and supervising this study.
Acknowledgments
We thank the reviewers for helpful and constructive comments on earlier draft of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.00042/full#supplementary-material
Supplementary Table 1Swinger transformed version of 347 ESTs mapped on human genome.
Supplementary Table 2Whole cell transcriptome BLAST result for swinger transformed ESTs mapped on non coding genomic region.
References
1
AhmedS. F.DebS.PaulI.ChatterjeeA.MandalT.ChatterjeeU.et al. (2012). The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J. Biol. Chem.287, 15996–16006. doi: 10.1074/jbc.M111.321083
2
BéguinP.GillS.CharpinN.ForterreP. (2015). Synergistic template-free synthesis of dsDNA by Thermococcus nautili primase PolpTN2, DNA polymerase PolB, and pTN2 helicase. Extremophiles19 (1), 69–76. doi: 10.1007/s00792-014-0706-1
3
BahnJ. H.LeeJ. H.LiG.GreerC.PengG.XiaoX. (2012). Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res.22, 142–150. doi: 10.1101/gr.124107.111
4
Bar-YaacovD.AvitalG.LevinL.RichardsA. L.HachenN.Rebolledo JaramilloB.et al. (2013). RNA-DNA differences in human mitochondria restore ancestral form of 16S ribosomal RNA. Genome Res.23, 1789–1796. doi: 10.1101/gr.161265.113
5
BassB. L. (2002). RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem.71, 817–846. doi: 10.1146/annurev.biochem.71.110601.135501
6
BlankA.GallantJ. A.BurgessR. R.LoebL. A. (1986). An RNA polymerase mutant with reduced accuracy of chain elongation. Biochemistry25, 5920–5928. doi: 10.1021/bi00368a013
7
BullerdiekJ.RommelB. (2018). Factors targeting MED12 to drive tumorigenesis?F1000Research7, 359. doi: 10.12688/f1000research.14227.1
8
ChenC.BundschuhR. (2012). Systematic investigation of insertional and deletional RNA-DNA differences in the human transcriptome. BMC Genomics13, 616. doi: 10.1186/1471-2164-13-616
9
CioccaD. R.CalderwoodS. K. (2005). Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones10 (2), 86–103. doi: 10.1379/CSC-99r.1
10
CollavinL.LazarevičD.UtreraR.MarzinottoS.MonteM.SchneiderC. (1999). wt p53 dependent expression of a membrane-associated isoform of adenylate kinase. Oncogene18, 5879–5888. doi: 10.1038/sj.onc.1202970
11
DunhamI.KundajeA.AldredS. F.CollinsP. J.DavisC. A.DoyleF.et al. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature489 (7414), 57–74. doi: 10.1038/nature11247
12
EisermannK.DarJ. A.DongJ.WangD.MasoodiK. Z.WangZ. (2015). Poly (A) binding protein cytoplasmic 1 is a novel co-regulator of the androgen receptor. PloS One10 (7), e0128495. doi: 10.1371/journal.pone.0128495
13
El HoumamiN.SeligmannH. (2017). Evolution of nucleotide punctuation marks: from structural to linear signals. Front. Genet.27, 8. doi: 10.3389/fgene.2017.00036
14
FagerbergL.HallstromB. M.OksvoldP.KampfC.DjureinovicD.OdebergJ.et al. (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteomics13(2), 397–406. doi: 10.1074/mcp.M113.035600
15
GarzonR.VoliniaS.PapaioannouD.NicoletD.KohlschmidtJ.YanP. S.et al. (2014). Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A.111 (52), 18679–18684. doi: 10.1073/pnas.1422050112
16
GaudeH.AznarN.DelayA.BresA.Buchet-PoyauK.CaillatC.et al. (2012). Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1. Oncogene31, 1582–1591. doi: 10.1038/onc.2011.342
17
HatakeyamaS.WatanabeM.FujiiY.NakayamaK. I. (2005). Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation. Cancer Res.65, 7874–7879. doi: 10.1158/0008-5472.CAN-05-1581
18
JanY. H.LaiT. C.YangC. J.HuangM. S.HsiaoM. (2019). A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma. Sci. Rep.9 (1), 12329. doi: 10.1038/s41598-019-48243-9
19
JanssenE.KuiperJ.HodgsonD.ZingmanL. V.AlekseevA. E.TerzicA.et al. (2004). Two structurally distinct and spatially compartmentalized adenylate kinases are expressed from the AK1 gene in mouse brain. Mol. Cell. Biochem.256-257, 59–72. doi: 10.1023/B:MCBI.0000009859.15267.db
20
KajiroM.HirotaR.NakajimaY.KawanowaK.So-MaK.ItoI.et al. (2009). The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat. Cell Biol.11, 312–319. doi: 10.1038/ncb1839
21
KandelE. S.NudlerE. (2002). Template switching by RNA polymerase II in vivo: evidence and implications from a retroviral system. Mol. Cell. 10 (6), 1495–1502. doi: 10.1016/S1097-2765(02)00777-3
22
KnippaK.PetersonD. O. (2013). Fidelity of RNA polymerase II transcription: role of Rbp9 in error detection and proofreading. Biochemistry52, 7807–7817. doi: 10.1021/bi4009566
23
Księżakowska-ŁakomaK.ŻyłaM.WilczyńskiJ. R. (2014). Mitochondrial dysfunction in cancer. Przeglad menopauzalny = Menopause Rev.13 (2), 136–144. doi: 10.5114/pm.2014.42717
24
KumarS.RazzaqS. K.VoA. D.GautamM.LiH. (2016). Identifying fusion transcripts using next generation sequencing. Wiley Interdiscip. Rev. RNA7 (6), 811–823. doi: 10.1002/wrna.1382
25
López-NievaP.Fernández-NavarroP.Graña-CastroO.Andrés-LeónE.SantosJ.Villa-MoralesM.et al. (2019). Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma. Sci. Rep. 9, 5179. doi: 10.1038/s41598-019-41675-3
26
LöytynojaA.GoldmanN. (2017). Short template switch events explain mutation clusters in the human genome. Genome Res. 27 (6), 1039–1049. doi: 10.1101/gr.214973.116
27
LeeH. R.JohnsonK. A. (2006). Fidelity of the human mitochondrial DNA polymerase. J. Biol. Chem.281, 36236–36240. doi: 10.1074/jbc.M607964200
28
LeeJ. A.CarvalhoC. M. B.LupskiJ. R. (2007). A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell.131(7), 1235–1247. doi: 10.1016/j.cell.2007.11.037
29
LeeS. Y.JoungJ. G.ParkC. H.ParkJ. H.KimJ. H. (2015). RCARE: RNA Sequence Comparison and Annotation for RNA Editing. BMC Med. Genomics8 (2), S8. doi: 10.1186/1755-8794-8-S2-S8
30
LiM.WangI. X.LiY.BruzelA.RichardsA. L.ToungJ. M.et al. (2011). Widespread RNA and DNA sequence differences in the human transcriptome. Science333 (6038), 53–58. doi: 10.1126/science.1207018
31
LiL.ZengQ.BhutkarA.GalvánJ. A.KaramitopoulouE.NoordermeerD.et al. (2018). GKAP acts as a genetic modulator of NMDAR signaling to govern invasive tumor growth. Cancer Cell33 (4), 736–751. doi: 10.1016/j.ccell.2018.02.011
32
LinC. S.LiuL. T.OuL. H.PanS. C.LinC. I.WeiY. H. (2018). Role of mitochondrial function in the invasiveness of human colon cancer cells. Oncol. Rep. 39 (1), 316–330. doi: 10.3892/or.2017.6087
33
LiuD.YinB.WangQ.JuW.ChenY.QiuH.et al. (2012). Cytoplasmic Poly(A) binding protein 4 is highly expressed in human colorectal cancer and correlates with better prognosis. J. Genet. Genomics. 39 (8), 369–374 doi: 10.1016/j.jgg.2012.05.007
34
MaY.ChenY.PetersenI. (2017). Expression and epigenetic regulation of cystatin B in lung cancer and colorectal cancer. Pathol. Res. Pract. 213 (12), 1568–1574. doi: 10.1016/j.prp.2017.06.007
35
MichelC. J.SeligmannH. (2014). Bijective transformation circular codes and nucleotide exchanging RNA transcription. BioSystems. 118 (1), 39–50. doi: 10.1016/j.biosystems.2014.02.002
36
Modica-NapolitanoJ. S.SinghK. K. (2004). Mitochondrial dysfunction in cancer. Mitochondrion. 4 (5–6 SPEC. ISS.), 755–762. doi: 10.1016/j.mito.2004.07.027
37
MorgulisA.CoulourisG.RaytselisY.MaddenT. L.AgarwalaR.SchäfferA. A. (2008). Database indexing for production MegaBLAST searches. Bioinformatics24 (16), 1757–1764. doi: 10.1093/bioinformatics/btn322
38
NetoE. D.CorreaR. G.Verjovski-AlmeidaS.BrionesM. R. S.NagaiM. A.Da SilvaW.et al. (2000). Shotgun sequencing of the human transcriptome with ORF expressed sequence tags. Proc. Natl. Acad. Sci. U. S. A. 97, 3491–3496. doi: 10.1073/pnas.97.7.3491
39
NinioJ. (1991). Connections between translation, transcription and replication error-rates. Biochimie.73, 1517–1523. doi: 10.1016/0300-9084(91)90186-5
40
ParejaF.Da Cruz PaulaA.MurrayM. P.HoangT.Gularte-MéridaR.BrownD.et al. (2019). Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. J. Clin. Pathol. 72 (3), 258–262. doi: 10.1136/jclinpath-2018-205570
41
ParkE.WilliamsB.WoldB. J.MortazaviA. (2012). RNA editing in the human ENCODE RNA-seq data. Genome Res.22, 1626–1633. doi: 10.1101/gr.134957.111
42
PiovesanA.CaracausiM.AntonarosF.PelleriM. C.VitaleL. (2016). GeneBase 1.1: a tool to summarize data from NCBI gene datasets and its application to an update of human gene statistics. Database J. Biol. Database Curation. 2016, 1–13. doi: 10.1093/database/baw153
43
PorathH. T.CarmiS.LevanonE. Y. (2014). A genome-wide map of hyper-edited RNA reveals numerous new sites. Nat. Commun. 5, 4726. doi: 10.1038/ncomms5726
44
RuckovaE.MullerP.NenutilR.VojtesekB. (2012). Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer. Cell. Mol. Biol. Lett.17, 446–458. doi: 10.2478/s11658-012-0021-8
45
SchaubM.KellerW. (2002). RNA editing by adenosine deaminases generates RNA and protein diversity. Biochimie. 84 (8), 791–803. doi: 10.1016/S0300-9084(02)01446-3
46
SeligmannH.RaoultD. (2018). Stem-loop RNA hairpins in giant viruses: Invading rRNA-like repeats and a template free RNA. Front. Microbiol. 9, 101. doi: 10.3389/fmicb.2018.00101
47
SeligmannH.WarthiG. (2019). Chimeric translation for mitochondrial peptides: regular and expanded codons. Comput. Struct. Biotech. J.17, 1195–1202. doi: 10.1016/j.csbj.2019.08.006
48
SeligmannH. (2012). Overlapping genes coded in the 3'-to-5'-direction in mitochondrial genes and 3'-to-5' polymerization of non-complementary RNA by an ‘invertase'. J. Theor. Biol.315, 38–52. doi: 10.1016/j.jtbi.2012.08.044
49
SeligmannH. (2013a). “Replicational Mutation Gradients, Dipole Moments, Nearest Neighbour Effects and DNA Polymerase Gamma Fidelity in Human Mitochondrial Genomes,” in The Mechanisms of DNA Replication. Ed. StuartD. (London: InTech, chpater10), 257–286. doi: 10.5772/51245
50
SeligmannH. (2013b). Polymerization of non-complementary RNA: Systematic symmetric nucleotide exchanges mainly involving uracil produce mitochondrial RNA transcripts coding for cryptic overlapping genes. BioSystems111, 156–174. doi: 10.1016/j.biosystems.2013.01.011
51
SeligmannH. (2013c). Systematic asymmetric nucleotide exchanges produce human mitochondrial RNAs cryptically encoding for overlapping protein coding genes. J. Theor. Biol.324, 1–20. doi: 10.1016/j.jtbi.2013.01.024
52
SeligmannH. (2014a). Species radiation by DNA replication that systematically exchanges nucleotides?J. Theor. Biol.363, 216–222. doi: 10.1016/j.jtbi.2014.08.036
53
SeligmannH. (2014b). Mitochondrial swinger replication: DNA replication systematically exchanging nucleotides and short 16S ribosomal DNA swinger inserts. BioSystems125, 22–31. doi: 10.1016/j.biosystems.2014.09.012
54
SeligmannH. (2015a). Swinger RNAs with sharp switches between regular transcription and transcription systematically exchanging ribonucleotides: Case studies. BioSystems135, 1–8. doi: 10.1016/j.biosystems.2015.07.003
55
SeligmannH. (2015b). Sharp switches between regular and swinger mitochondrial replication: 16S rDNA systematically exchanging nucleotides A<- > T+C<- > G in the mitogenome of Kamimuria wangi. Mitochondrial DNA27 (4), 2440–2446. doi: 10.3109/19401736.2015.1033691
56
SeligmannH. (2015c). Codon expansion and systematic transcriptional deletions produce tetra-, pentacoded mitochondrial peptides. J. Theor. Biol.387, 154–165. doi: 10.1016/j.jtbi.2015.09.030
57
SeligmannH. (2016a). Natural chymotrypsin-like-cleaved human mitochondrial peptides confirm tetra-, pentacodon, non-canonical RNA translations. BioSystems147, 78–93. doi: 10.1016/j.biosystems.2016.07.010
58
SeligmannH. (2016b). Translation of mitochondrial swinger RNAs according to tri-, tetra- and pentacodons. BioSystems140, 38–48. doi: 10.1016/j.biosystems.2015.11.009
59
SeligmannH. (2016c). Unbiased mitoproteome analyses confirm non-canonical RNA, expanded codon translations. Comput. Struct. Biotechnol. J. 14, 391–403. doi: 10.1016/j.csbj.2016.09.004
60
SeligmannH. (2016d). Chimeric mitochondrial peptides from contiguous regular and swinger RNA. Comput. Struct. Biotechnol. J.14, 283–297. doi: 10.1016/j.csbj.2016.06.005
61
SeligmannH. (2016e). Swinger RNA self-hybridization and mitochondrial non-canonical swinger transcription, transcription systematically exchanging nucleotides. J. Theor. Biol.399, 84–91. doi: 10.1016/j.jtbi.2016.04.007
62
SeligmannH. (2016f). Systematically frameshifting by deletion of every 4th or 4th and 5th nucleotides during mitochondrial transcription: RNA self-hybridization regulates delRNA expression. Biosystems142-143, 43–51. doi: 10.1016/j.biosystems.2016.03.009
63
SeligmannH. (2017a). Natural mitochondrial proteolysis confirms transcription systematically exchanging/deleting nucleotides, peptides coded by expanded codons. J. Theor. Biol.414, 76–90. doi: 10.1016/j.jtbi.2016.11.021
64
SeligmannH. (2017b). Reviewing evidence for systematic transcriptional deletions, nucleotide exchanges, and expanded codons, and peptide clusters in human mitochondria. BioSystems160, 10–24. doi: 10.1016/j.biosystems.2017.08.002
65
SeligmannH. (2018). Bijective codon transformations show genetic code symmetries centered on cytosine's coding properties. Theory Biosci137, 17–31. doi: 10.1007/s12064-017-0258-x
66
SinghA.ZahraS.DasD.KumarS. (2019). “AtFusionDB: a database of fusion transcripts in Arabidopsis thaliana. Database2019, 1–9. doi: 10.1093/database/bay135
67
StrathernJ. N.JinD. J.CourtD. L.KashlevM. (2012). Isolation and characterization of transcription fidelity mutants. Biochim. Biophys. Acta - Gene Regul. Mech. 1819, 694–699. doi: 10.1016/j.bbagrm.2012.02.005
68
TarantulV.NikolaevA.HannigH.KalmyrzaevB.MuchoyanI.MaximovV.et al. (2001). Detection of abundantly transcribed genes and gene translocation in human immunodeficiency virus - Associated non-hodgkin's lymphoma. Neoplasia3 (2), 132–142. doi: 10.1038/sj.neo.7900137
69
VasseurS.MalicetC.CalvoE. L.DagornJ. C.IovannaJ. L. (2005). Gene expression profiling of tumours derived from rasv12/E1A-transformed mouse embryonic fibroblasts to identify genes required for tumour development. Mol. Cancer4 (1), 4. doi: 10.1186/1476-4598-4-4
70
WangS.WuX.ZhangJ.ChenY.XuJ.XiaX.et al. (2013). CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut.62, 496–508. doi: 10.1136/gutjnl-2011-301522
71
WangI. X.CoreL. J.KwakH.BradyL.BruzelA.McDanielL.et al. (2014). RNA-DNA differences are generated in human cells within seconds after RNA exits polymerase II. Cell Rep.6, 906–915. doi: 10.1016/j.celrep.2014.01.037
72
WangT.YangJ.XuJ.LiJ.CaoZ.ZhouL.et al. (2014a). CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Oncotarget.5, 1969–1986. doi: 10.18632/oncotarget.1890
73
WangY.RenF.WangY.FengY.WangD.JiaB.et al. (2014b). CHIP/Stub1 functions as a tumor suppressor and represses NF-κB-mediated signaling in colorectal cancer. Carcinogenesis35, 983–991. doi: 10.1093/carcin/bgt393
74
WangI. X.GrunseichC.ChungY. G.KwakH.RamrattanG.ZhuZ.et al. (2016). RNA-DNA sequence differences in Saccharomyces cerevisiae. Genome Res.26, 1544–1554. doi: 10.1101/gr.207878.116
75
WarthiG.SeligmannH. (2018). “Swinger RNAs in the Human Mitochondrial Transcriptome,” in In mitochondrial DNA-new insights. Eds. SeligmannH.WarthiG., (London) 79–92. Chapter 4. doi: 10.5772/intechopen.80805
76
WarthiG.SeligmannH. (2019). Transcripts with systematic nucleotide deletion of 1-12 nucleotide in human mitochondrion suggest potential non-canonical transcription. PloS One14, e0217356. doi: 10.1371/journal.pone.0217356
77
WarthiG.FournierPE.SeligmannH. (2019). Identification of noncanonical transcripts produced by systematic nucleotide exchanges in HIV-associated centroblastic lymphoma. DNA Cell Biol. doi: 10.1089/dna.2019.5066 [Epub ahead of print]
78
XieJ.UbangoJ.BanY.ChakravartiD.KimJ. J.WeiJ. J. (2018). Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations. Genes Chromosom. Cancer57 (10), 485–494. doi: 10.1002/gcc.22643
79
YingZ.HaiyanG.HaidongG. (2013). BAG5 regulates PTEN stability in MCF-7 cell line. BMB Rep.46, 490–494. doi: 10.5483/BMBRep.2013.46.10.268
80
ZengM.LiF.WangL.ChenC.HuangX.WuX.et al. (2018). Downregulated cytoplasmic polyadenylation element-binding protein-4 is associated with the carcinogenesis of head and neck squamous cell carcinoma. Oncol. Lett.15 (3), 3226–3232. doi: 10.3892/ol.2017.7661
81
ZhangZ.SchwartzS.WagnerL.MillerW. (2000). A greedy algorithm for aligning DNA sequences. J. Comput. Biol. 7 (1–2), 203–214. doi: 10.1089/10665270050081478
82
ZhangJ.ShiZ. F.HuangJ. X.ZouX. G. (2016). CSTB downregulation promotes cell proliferation and migration and suppresses apoptosis in gastric cancer SGC-7901 cell line. Oncol. Res. 24 (6), 487–494. doi: 10.3727/096504016X14685034103752
83
ZhouY. N.LubkowskaL.HuiM.CourtC.ChenS.CourtD. L.et al. (2013). Isolation and characterization of RNA polymerase rpoB mutations that alter transcription slippage during elongation in Escherichia coli. J. Biol. Chem.288, 2700–2710. doi: 10.1074/jbc.M112.429464
Summary
Keywords
swinger RNAs, systematic nucleotide exchanges, transcriptome, cDNA, cancer
Citation
Warthi G, Fournier P-E and Seligmann H (2020) Systematic Nucleotide Exchange Analysis of ESTs From the Human Cancer Genome Project Report: Origins of 347 Unknown ESTs Indicate Putative Transcription of Non-Coding Genomic Regions. Front. Genet. 11:42. doi: 10.3389/fgene.2020.00042
Received
28 October 2019
Accepted
15 January 2020
Published
11 February 2020
Volume
11 - 2020
Edited by
Dapeng Wang, University of Leeds, United Kingdom
Reviewed by
Rachita Yadav, Harvard Medical School, United States; Hauke Busch, Universität zu Lübeck, Germany
Updates
Copyright
© 2020 Warthi, Fournier and Seligmann.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ganesh Warthi, g.warthi6791@gmail.com
This article was submitted to Bioinformatics and Computational Biology, a section of the journal Frontiers in Genetics
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.